Cellular	O
disposition	O
of	O
sulphamethoxazole	O
and	O
its	O
metabolites	O
:	O
implications	O
for	O
hypersensitivity	O
.	O

1.	O
Bioactivation	O
of	O
sulphamethoxazole	O
(	O
SMX	O
)	O
to	O
chemically-reactive	O
metabolites	O
and	O
subsequent	O
protein	O
conjugation	O
is	O
thought	O
to	O
be	O
involved	O
in	O
SMX	O
hypersensitivity	O
.	O

We	O
have	O
therefore	O
examined	O
the	O
cellular	O
metabolism	O
,	O
disposition	O
and	O
conjugation	O
of	O
SMX	O
and	O
its	O
metabolites	O
in	O
vitro	O
.	O

2.	O
Flow	O
cytometry	O
revealed	O
binding	O
of	O
N-hydroxy	O
(	O
SMX-NHOH	O
)	O
and	O
nitroso	O
(	O
SMX-NO	O
)	O
metabolites	O
of	O
SMX	O
,	O
but	O
not	O
of	O
SMX	O
itself	O
,	O
to	O
the	O
surface	O
of	O
viable	O
white	B-cell_type
blood	I-cell_type
cells	I-cell_type
.	O

Cellular	O
haptenation	O
by	O
SMX-NO	O
was	O
reduced	O
by	O
exogenous	O
glutathione	O
(	O
GSH	O
)	O
.	O

3.	O
SMX-NHOH	O
and	O
SMX-NO	O
were	O
rapidly	O
reduced	O
back	O
to	O
the	O
parent	O
compound	O
by	O
cysteine	O
(	O
CYS	O
)	O
,	O
GSH	O
,	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
plasma	O
,	O
suggesting	O
that	O
this	O
is	O
an	O
important	O
and	O
ubiquitous	B-protein
bioinactivation	O
mechanism	O
.	O

4.	O
Fluorescence	O
HPLC	O
showed	O
that	O
SMX-NHOH	O
and	O
SMX-NO	O
depleted	O
CYS	O
and	O
GSH	O
in	O
buffer	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
cells	O
and	O
plasma	O
.	O

5.	O
Neutrophil	O
apoptosis	O
and	O
inhibition	O
of	O
neutrophil	O
function	O
were	O
induced	O
at	O
lower	O
concentrations	O
of	O
SMX-NHOH	O
and	O
SMX-NO	O
than	O
those	O
inducing	O
loss	O
of	O
membrane	O
viability	O
,	O
with	O
SMX	O
having	O
no	O
effect	O
.	O

Lymphocytes	B-cell_type
were	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
more	O
sensitive	O
to	O
the	O
direct	O
cytotoxic	O
effects	O
of	O
SMX-NO	O
than	O
neutrophils	B-cell_type
.	O

6.	O
Partitioning	O
of	O
SMX-NHOH	O
into	O
red	B-cell_type
blood	I-cell_type
cells	I-cell_type
was	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
lower	O
than	O
with	O
the	O
hydroxylamine	O
of	O
dapsone	O
.	O

7.	O
Our	O
results	O
suggest	O
that	O
the	O
balance	O
between	O
oxidation	O
of	O
SMX	O
to	O
its	O
toxic	O
metabolites	O
and	O
their	O
reduction	O
is	O
an	O
important	O
protective	O
cellular	O
mechanism	O
.	O

If	O
an	O
imbalance	O
exists	O
,	O
haptenation	O
of	O
the	O
toxic	O
metabolites	O
to	O
bodily	O
proteins	O
including	O
the	O
surface	O
of	O
viable	O
cells	O
can	O
occur	O
,	O
and	O
may	O
result	O
in	O
drug	O
hypersensitivity	O
.	O

British	NULL
Journal	NULL
of	NULL
Pharmacology	NULL
(	NULL
1999	NULL
)	NULL
126	NULL
,	NULL
1393-1407	NULL
©	NULL
1999	NULL
Stockton	NULL
Press	NULL
_	NULL
All	NULL
rights	NULL
reserved	NULL
0007-1188/99	NULL
$	NULL
12.00	NULL
http	NULL
:	NULL
//www.stockton-press.co.uk/bjp	NULL
Cellular	NULL
disposition	NULL
of	NULL
sulphamethoxazole	NULL
and	NULL
its	NULL
metabolites	NULL
:	NULL
implications	NULL
for	NULL
hypersensitivity	NULL
'Dean	NULL
J.	NULL
Naisbitt	NULL
,	NULL
'Sally	NULL
J.	NULL
Hough	NULL
,	NULL
'Helen	NULL
J.	NULL
Gill	NULL
,	NULL
'Munir	NULL
Pirmohamed	NULL
,	NULL
'Neil	NULL
R.	NULL
Kitteringham	NULL
&	NULL
**B	NULL
,	NULL
Kevin	NULL
Park	NULL
'Department	NULL
of	NULL
Pharmacology	NULL
and	NULL
Therapeutics	NULL
,	NULL
The	NULL
University	NULL
of	NULL
Liverpool	NULL
,	NULL
P.O	NULL
.	NULL

Box	NULL
147	NULL
,	NULL
Liverpool	NULL
,	NULL
Merseyside	NULL
L69	NULL
3GE	NULL
1	NULL
Bioactivation	NULL
of	NULL
sulphamethoxazole	NULL
(	NULL
SMX	NULL
)	NULL
to	NULL
chemically-reactive	NULL
metabolites	NULL
and	NULL
subsequent	NULL
protein	NULL
conjugation	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
SMX	NULL
hypersensitivity	NULL
.	NULL

We	NULL
have	NULL
therefore	NULL
examined	NULL
the	NULL
cellular	NULL
metabolism	NULL
,	NULL
disposition	NULL
and	NULL
conjugation	NULL
of	NULL
SMX	NULL
and	NULL
its	NULL
metabolites	NULL
in	NULL
vitro	NULL
.	NULL

2	NULL
Flow	NULL
cytometry	NULL
revealed	NULL
binding	NULL
of	NULL
N-hydroxy	NULL
(	NULL
SMX-NHOH	NULL
)	NULL
and	NULL
nitroso	NULL
(	NULL
SMX-NO	NULL
)	NULL
metabolites	NULL
of	NULL
SMX	NULL
,	NULL
but	NULL
not	NULL
of	NULL
SMX	NULL
itself	NULL
,	NULL
to	NULL
the	NULL
surface	NULL
of	NULL
viable	NULL
white	NULL
blood	NULL
cells	NULL
.	NULL

Cellular	NULL
haptenation	NULL
by	NULL
SMX-NO	NULL
was	NULL
reduced	NULL
by	NULL
exogenous	NULL
glutathione	NULL
(	NULL
GSH	NULL
)	NULL
.	NULL

3	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
were	NULL
rapidly	NULL
reduced	NULL
back	NULL
to	NULL
the	NULL
parent	NULL
compound	NULL
by	NULL
cysteine	NULL
(	NULL
CYS	NULL
)	NULL
,	NULL
GSH	NULL
,	NULL
human	NULL
peripheral	NULL
blood	NULL
cells	NULL
and	NULL
plasma	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
is	NULL
an	NULL
important	NULL
and	NULL
ubiquitous	NULL
bioinactivation	NULL
mechanism	NULL
.	NULL

4	NULL
-	NULL
Fluorescence	NULL
HPLC	NULL
showed	NULL
that	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
depleted	NULL
CYS	NULL
and	NULL
GSH	NULL
in	NULL
buffer	NULL
,	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
,	NULL
in	NULL
cells	NULL
and	NULL
plasma	NULL
.	NULL

5	NULL
-	NULL
Neutrophil	NULL
apoptosis	NULL
and	NULL
inhibition	NULL
of	NULL
neutrophil	NULL
function	NULL
were	NULL
induced	NULL
at	NULL
lower	NULL
concentrations	NULL
of	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
than	NULL
those	NULL
inducing	NULL
loss	NULL
of	NULL
membrane	NULL
viability	NULL
,	NULL
with	NULL
SMX	NULL
having	NULL
no	NULL
effect	NULL
.	NULL

Lymphocytes	NULL
were	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
more	NULL
sensitive	NULL
to	NULL
the	NULL
direct	NULL
cytotoxic	NULL
effects	NULL
of	NULL
SMX-NO	NULL
than	NULL
neutrophils	NULL
.	NULL

6	NULL
-	NULL
Partitioning	NULL
of	NULL
SMX-NHOH	NULL
into	NULL
red	NULL
blood	NULL
cells	NULL
was	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
lower	NULL
than	NULL
with	NULL
the	NULL
hydroxylamine	NULL
of	NULL
dapsone	NULL
.	NULL

7	NULL
Our	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
balance	NULL
between	NULL
oxidation	NULL
of	NULL
SMX	NULL
to	NULL
its	NULL
toxic	NULL
metabolites	NULL
and	NULL
their	NULL
reduction	NULL
is	NULL
an	NULL
important	NULL
protective	NULL
cellular	NULL
mechanism	NULL
.	NULL

If	NULL
an	NULL
imbalance	NULL
exists	NULL
,	NULL
haptenation	NULL
of	NULL
the	NULL
toxic	NULL
metabolites	NULL
to	NULL
bodily	NULL
proteins	NULL
including	NULL
the	NULL
surface	NULL
of	NULL
viable	NULL
cells	NULL
can	NULL
occur	NULL
,	NULL
and	NULL
may	NULL
result	NULL
in	NULL
drug	NULL
hypersensitivity	NULL
.	NULL

Keywords	NULL
:	NULL
Sulphamethoxazole	NULL
;	NULL
hypersensitivity	NULL
;	NULL
cellular	NULL
disposition	NULL
;	NULL
haptenation	NULL
;	NULL
reduction	NULL
Abbreviations	NULL
:	NULL
CYS	NULL
,	NULL
cysteine	NULL
;	NULL
DMSO	NULL
,	NULL
dimethylsulphoxide	NULL
;	NULL
FITC	NULL
,	NULL
fluorescein	NULL
isothiocyanate	NULL
;	NULL
GSH	NULL
,	NULL
glutathione	NULL
;	NULL
LC-MS	NULL
,	NULL
liquid	NULL
chromatography-mass	NULL
spectroscopy	NULL
;	NULL
MetHb	NULL
,	NULL
methaemoglobin	NULL
;	NULL
NADPH	NULL
,	NULL
A-nicotinamide	NULL
adenine	NULL
dinucleotide	NULL
;	NULL
PBS	NULL
,	NULL
phosphate	NULL
buffered	NULL
saline	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
SMX	NULL
,	NULL
sulphamethoxazole	NULL
;	NULL
SMX-NHOH	NULL
,	NULL
sulphamethoxazole	NULL
hydroxylamine	NULL
;	NULL
SMX-NO	NULL
,	NULL
nitroso	NULL
sulphamethoxazole	NULL
Introduction	NULL
Sulphonamides	NULL
cause	NULL
a	NULL
variety	NULL
of	NULL
unpredictable	NULL
idiosyncratic	NULL
drug	NULL
reactions	NULL
including	NULL
fever	NULL
,	NULL
lymphadenopathy	NULL
,	NULL
skin	NULL
rashes	NULL
,	NULL
hepatitis	NULL
,	NULL
nephritis	NULL
and	NULL
blood	NULL
dyscrasias	NULL
in	NULL
about	NULL
2-3	NULL
%	NULL
of	NULL
patients	NULL
(	NULL
Mandell	NULL
&	NULL
Sande	NULL
,	NULL
1985	NULL
)	NULL
.	NULL

In	NULL
the	NULL
U.K.	NULL
,	NULL
this	NULL
has	NULL
resulted	NULL
in	NULL
restricted	NULL
indications	NULL
for	NULL
drugs	NULL
such	NULL
as	NULL
co-trimoxazole	NULL
(	NULL
Saiag	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Pirmohamed	NULL
&	NULL
Park	NULL
,	NULL
1995	NULL
)	NULL
,	NULL
a	NULL
combination	NULL
of	NULL
sulphamethoxazole	NULL
(	NULL
SMX	NULL
)	NULL
and	NULL
trimetho-prim	NULL
.	NULL

The	NULL
hypersensitivity	NULL
reactions	NULL
have	NULL
been	NULL
attributed	NULL
to	NULL
the	NULL
sulphonamide	NULL
component	NULL
(	NULL
Cribb	NULL
et	NULL
al	NULL
.	NULL

,	NULL
19962	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
main	NULL
uses	NULL
of	NULL
co-trimoxazole	NULL
is	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
Pneumocystis	NULL
carinii	NULL
pneumonia	NULL
in	NULL
HIV-infected	NULL
patients	NULL
.	NULL

In	NULL
comparative	NULL
studies	NULL
with	NULL
other	NULL
agents	NULL
such	NULL
as	NULL
dapsone	NULL
and	NULL
pentamidine	NULL
,	NULL
co-trimoxazole	NULL
has	NULL
been	NULL
found	NULL
to	NULL
be	NULL
the	NULL
most	NULL
efficacious	NULL
,	NULL
both	NULL
for	NULL
acute	NULL
treatment	NULL
and	NULL
for	NULL
prophylaxis	NULL
(	NULL
Smith	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
rate	NULL
of	NULL
adverse	NULL
reactions	NULL
in	NULL
HIV-infected	NULL
patients	NULL
is	NULL
significantly	NULL
higher	NULL
than	NULL
in	NULL
seronegative	NULL
patients	NULL
severely	NULL
limiting	NULL
its	NULL
usefulness	NULL
(	NULL
Carr	NULL
&	NULL
Cooper	NULL
,	NULL
1995	NULL
;	NULL
Koopmans	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Pirmohamed	NULL
&	NULL
Park	NULL
,	NULL
1995	NULL
;	NULL
Tschachler	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
types	NULL
of	NULL
reactions	NULL
are	NULL
similar	NULL
to	NULL
those	NULL
observed	NULL
in	NULL
HIV-negative	NULL
individuals	NULL
and	NULL
occur	NULL
within	NULL
5-15	NULL
days	NULL
of	NULL
the	NULL
start	NULL
*	NULL
Author	NULL
for	NULL
correspondence	NULL
;	NULL
E-mail	NULL
:	NULL
bkpark	NULL
@	NULL
liv.ac.uk	NULL
of	NULL
therapy	NULL
,	NULL
although	NULL
in	NULL
general	NULL
,	NULL
they	NULL
are	NULL
more	NULL
severe	NULL
(	NULL
Anonymous	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

Virus-induced	NULL
changes	NULL
in	NULL
drug	NULL
metabolism	NULL
and	NULL
drug	NULL
detoxification	NULL
,	NULL
in	NULL
particular	NULL
a	NULL
change	NULL
in	NULL
cellular	NULL
redox	NULL
potential	NULL
,	NULL
immune	NULL
dysregulation	NULL
,	NULL
drug-drug	NULL
interactions	NULL
and	NULL
drug	NULL
dosage	NULL
have	NULL
all	NULL
been	NULL
postulated	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
increased	NULL
risk	NULL
of	NULL
hypersensitivity	NULL
in	NULL
HIV-infected	NULL
patients	NULL
(	NULL
Carr	NULL
&	NULL
Cooper	NULL
,	NULL
1995	NULL
;	NULL
Pirmohamed	NULL
&	NULL
Park	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
identify	NULL
the	NULL
exact	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
of	NULL
SMX	NULL
hypersensitivity	NULL
in	NULL
HIV-infected	NULL
patients	NULL
in	NULL
order	NULL
to	NULL
develop	NULL
strategies	NULL
to	NULL
prevent	NULL
the	NULL
reactions	NULL
and	NULL
thus	NULL
improve	NULL
the	NULL
tolerability	NULL
of	NULL
co-trimox-azole	NULL
.	NULL

SMX	NULL
is	NULL
metabolized	NULL
not	NULL
only	NULL
to	NULL
stable	NULL
metabolites	NULL
,	NULL
such	NULL
as	NULL
the	NULL
N-acetate	NULL
and	NULL
glucuronide	NULL
but	NULL
also	NULL
to	NULL
a	NULL
potentially	NULL
toxic	NULL
hydroxylamine	NULL
metabolite	NULL
(	NULL
SMX-NHOH	NULL
)	NULL
,	NULL
which	NULL
can	NULL
undergo	NULL
further	NULL
oxidation	NULL
to	NULL
a	NULL
nitroso	NULL
metabolite	NULL
(	NULL
SMX-NO	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
proposed	NULL
that	NULL
SMX-NO	NULL
is	NULL
responsible	NULL
for	NULL
idiosyncratic	NULL
toxicity	NULL
,	NULL
with	NULL
the	NULL
tissue	NULL
injury	NULL
occurring	NULL
via	NULL
an	NULL
immune-mediated	NULL
mechanism	NULL
(	NULL
Rieder	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
1989	NULL
;	NULL
1995a	NULL
,	NULL
b	NULL
;	NULL
Carr	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Meekins	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Cribb	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996b	NULL
)	NULL
.	NULL

In	NULL
an	NULL
in	NULL
vivo	NULL
rat	NULL
model	NULL
,	NULL
both	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
underwent	NULL
extensive	NULL
reduction	NULL
which	NULL
serves	NULL
as	NULL
a	NULL
detoxication	NULL
mechanism	NULL
(	NULL
Gill	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
measurement	NULL
of	NULL
urinary	NULL
concentrations	NULL
of	NULL
SMX-NHOH-estimated	NULL
to	NULL
be	NULL
about	NULL
2	NULL
%	NULL
of	NULL
an	NULL
ingested	NULL
dose	NULL
in	NULL
man	NULL
(	NULL
Gill	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
-may	NULL
underestimate	NULL
1394	NULL
D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
the	NULL
total	NULL
level	NULL
of	NULL
tissue	NULL
exposure	NULL
to	NULL
the	NULL
toxic	NULL
metabolites	NULL
.	NULL

Therefore	NULL
,	NULL
an	NULL
imbalance	NULL
between	NULL
oxidation	NULL
of	NULL
SMX	NULL
and	NULL
the	NULL
reduction	NULL
of	NULL
its	NULL
toxic	NULL
metabolites	NULL
back	NULL
to	NULL
the	NULL
parent	NULL
compound	NULL
may	NULL
predispose	NULL
to	NULL
toxicity	NULL
.	NULL

In	NULL
order	NULL
to	NULL
investigate	NULL
further	NULL
the	NULL
role	NULL
of	NULL
metabolism	NULL
in	NULL
SMX	NULL
toxicity	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
cellular	NULL
disposition	NULL
of	NULL
SMX	NULL
and	NULL
its	NULL
oxidative	NULL
metabolites	NULL
in	NULL
vitro	NULL
.	NULL

Methods	NULL
Materials	NULL
Bovine	NULL
and	NULL
human	NULL
serum	NULL
albumin	NULL
,	NULL
bromobimane	NULL
,	NULL
cysteine	NULL
(	NULL
CYS	NULL
)	NULL
,	NULL
dicuomarol	NULL
,	NULL
sulphoxide	NULL
(	NULL
DMSO	NULL
)	NULL
,	NULL
dap-sone	NULL
,	NULL
EDTA	NULL
,	NULL
glacial	NULL
acetic	NULL
acid	NULL
,	NULL
reduced	NULL
glutathione	NULL
(	NULL
GSH	NULL
)	NULL
,	NULL
neocuproin	NULL
,	NULL
reduced	NULL
nicotinamide	NULL
adenine	NULL
dinucleotide	NULL
phosphate	NULL
(	NULL
NADPH	NULL
)	NULL
,	NULL
NADH	NULL
,	NULL
N-ethyl	NULL
morpholine	NULL
,	NULL
D-L	NULL
thiolactone	NULL
homocysteine	NULL
,	NULL
o-phenylene	NULL
diamine	NULL
hydrochloride	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
propidium	NULL
iodide	NULL
,	NULL
RNAse	NULL
[	NULL
type	NULL
I-A	NULL
]	NULL
,	NULL
SMX	NULL
,	NULL
salicyl	NULL
hydroxamate	NULL
,	NULL
sodium	NULL
azide	NULL
,	NULL
sodium	NULL
citrate	NULL
,	NULL
trichloroacetic	NULL
acid	NULL
,	NULL
triethylamine	NULL
,	NULL
Tris	NULL
,	NULL
Tween	NULL
20	NULL
,	NULL
trypan	NULL
blue	NULL
,	NULL
FITC-conjugated	NULL
anti-rabbit	NULL
IgG	NULL
antibody	NULL
and	NULL
peroxidase-linked	NULL
anti-rat	NULL
IgG	NULL
antibody	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
(	NULL
Poole	NULL
,	NULL
U.K.	NULL
)	NULL
.	NULL

Anti-SMX	NULL
IgG	NULL
antibody	NULL
was	NULL
kindly	NULL
donated	NULL
by	NULL
Dr	NULL
A.E	NULL
.	NULL

Cribb	NULL
(	NULL
Merck	NULL
Research	NULL
Laboratories	NULL
,	NULL
West	NULL
Point	NULL
,	NULL
PA	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
were	NULL
synthesized	NULL
according	NULL
to	NULL
the	NULL
method	NULL
of	NULL
Naisbitt	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
and	NULL
found	NULL
to	NULL
be	NULL
>	NULL
99	NULL
%	NULL
pure	NULL
by	NULL
liquid	NULL
chromatography-mass	NULL
spectroscopy	NULL
(	NULL
LC-MS	NULL
)	NULL
and	NULL
NMR	NULL
(	NULL
Bruker	NULL
,	NULL
200	NULL
MHz	NULL
spectrometer	NULL
)	NULL
.	NULL

Monopoly	NULL
resolving	NULL
medium	NULL
(	NULL
Ficoll	NULL
Hypaque	NULL
,	NULL
1.114	NULL
g	NULL
ml-	NULL
'	NULL
)	NULL
and	NULL
Lymphoprep	NULL
(	NULL
1.077	NULL
g	NULL
ml~	NULL
``	NULL
)	NULL
were	NULL
from	NULL
ICN	NULL
Biomedicals	NULL
(	NULL
Bucks	NULL
.	NULL

,	NULL
U.K.	NULL
)	NULL
and	NULL
Nycomed	NULL
(	NULL
Birmingham	NULL
,	NULL
U.K.	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

All	NULL
HPLC-grade	NULL
solvents	NULL
were	NULL
purchased	NULL
from	NULL
Fischer	NULL
Scientific	NULL
(	NULL
Loughbor-ough	NULL
,	NULL
U.K.	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
peripheral	NULL
blood	NULL
cells	NULL
Human	NULL
neutrophils	NULL
,	NULL
lymphocytes	NULL
and	NULL
red	NULL
blood	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
heparinized	NULL
venous	NULL
blood	NULL
of	NULL
ten	NULL
healthy	NULL
male	NULL
volunteers	NULL
(	NULL
aged	NULL
19-45	NULL
)	NULL
on	NULL
a	NULL
dual	NULL
density	NULL
gradient	NULL
of	NULL
Monopoly	NULL
resolving	NULL
medium	NULL
and	NULL
Lymphoprep	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Naisbitt	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Neutrophils	NULL
and	NULL
lymphocytes	NULL
were	NULL
resuspended	NULL
in	NULL
Dulbecco	NULL
's	NULL
phosphate	NULL
buffered	NULL
saline	NULL
(	NULL
PBS	NULL
;	NULL
pH	NULL
7.4	NULL
)	NULL
and	NULL
diluted	NULL
to	NULL
the	NULL
concentration	NULL
required	NULL
for	NULL
each	NULL
experiment	NULL
.	NULL

Both	NULL
cell	NULL
types	NULL
were	NULL
greater	NULL
than	NULL
98	NULL
%	NULL
pure	NULL
and	NULL
97	NULL
%	NULL
viable	NULL
as	NULL
assessed	NULL
by	NULL
Wright	NULL
's	NULL
stain	NULL
and	NULL
trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
isolated	NULL
red	NULL
blood	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
and	NULL
resuspended	NULL
in	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
to	NULL
produce	NULL
a	NULL
haematocrit	NULL
of	NULL
50	NULL
%	NULL
.	NULL

When	NULL
required	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
with	NULL
a	NULL
sonic	NULL
probe	NULL
(	NULL
Heat	NULL
systems	NULL
,	NULL
Farmingdale	NULL
,	NULL
NY	NULL
,	NULL
U.S.A.	NULL
;	NULL
0°C	NULL
,	NULL
3	NULL
x	NULL
20	NULL
s	NULL
)	NULL
.	NULL

Platelet-free	NULL
plasma	NULL
was	NULL
prepared	NULL
from	NULL
ice-cold	NULL
heparinized	NULL
venous	NULL
blood	NULL
by	NULL
centrifugation	NULL
at	NULL
0°C	NULL
(	NULL
1200	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
)	NULL
.	NULL

All	NULL
samples	NULL
were	NULL
kept	NULL
on	NULL
ice	NULL
and	NULL
the	NULL
experiments	NULL
were	NULL
initiated	NULL
within	NULL
25	NULL
min	NULL
of	NULL
venepuncture	NULL
.	NULL

Thiolation	NULL
of	NULL
human	NULL
serum	NULL
albumin	NULL
Human	NULL
serum	NULL
albumin	NULL
(	NULL
200	NULL
mg	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
D.L-thiolactone	NULL
homocysteine	NULL
(	NULL
330	NULL
mg	NULL
)	NULL
in	NULL
PBS	NULL
(	NULL
4	NULL
ml	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
and	NULL
glycine	NULL
buffer	NULL
(	NULL
8	NULL
ml	NULL
,	NULL
100	NULL
um	NULL
glycine	NULL
in	NULL
100	NULL
uM	NULL
sodium	NULL
chloride	NULL
,	NULL
100	NULL
um	NULL
sodium	NULL
hydroxide	NULL
)	NULL
for	NULL
2h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
thiolated	NULL
albumin	NULL
was	NULL
then	NULL
washed	NULL
and	NULL
concentrated	NULL
using	NULL
a	NULL
Centriprep-10	NULL
column	NULL
(	NULL
1500	NULL
xg	NULL
for	NULL
2	NULL
h	NULL
;	NULL
Amicon	NULL
,	NULL
Glos	NULL
.	NULL

,	NULL
U.K.	NULL
)	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
thiolation	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Akerboom	NULL
&	NULL
Sies	NULL
(	NULL
1981	NULL
)	NULL
;	NULL
the	NULL
human	NULL
serum	NULL
albumin	NULL
:	NULL
thiol	NULL
ratio	NULL
increased	NULL
from	NULL
1:0.05-1:42	NULL
.	NULL

Reaction	NULL
of	NULL
sulphamethoxazole	NULL
,	NULL
sulphamethoxazole	NULL
hydroxylamine	NULL
and	NULL
nitroso	NULL
sulphamethoxazole	NULL
with	NULL
human	NULL
serum	NULL
albumin	NULL
and	NULL
thiolated	NULL
human	NULL
serum	NULL
albumin	NULL
Albumin	NULL
or	NULL
thiolated	NULL
albumin	NULL
(	NULL
100	NULL
mg	NULL
ml-	NULL
'	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
(	NULL
1-	NULL
1000	NULL
uM	NULL
)	NULL
in	NULL
PBS	NULL
(	NULL
pH	NULL
7.2	NULL
)	NULL
for	NULL
24	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Ninety-six	NULL
well	NULL
microtitre	NULL
plates	NULL
were	NULL
coated	NULL
with	NULL
100	NULL
ug	NULL
of	NULL
each	NULL
incubation	NULL
(	NULL
100	NULL
wl	NULL
)	NULL
in	NULL
PBS	NULL
overnight	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
plates	NULL
were	NULL
then	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
PBS	NULL
containing	NULL
0.05	NULL
%	NULL
Tween	NULL
20	NULL
(	NULL
PBS-Tween	NULL
)	NULL
before	NULL
incubation	NULL
with	NULL
anti-SMX	NULL
IgG	NULL
antibody	NULL
(	NULL
1/100	NULL
;	NULL
100	NULL
wl	NULL
)	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
antibody	NULL
was	NULL
raised	NULL
in	NULL
rats	NULL
immunized	NULL
with	NULL
SMX-NO	NULL
alone	NULL
(	NULL
Gill	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

The	NULL
wells	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
PBS-Tween	NULL
;	NULL
peroxidase-linked	NULL
anti-rat	NULL
IgG	NULL
antibody	NULL
in	NULL
PBS	NULL
(	NULL
dilution	NULL
1/2500	NULL
;	NULL
100	NULL
wl	NULL
)	NULL
was	NULL
then	NULL
added	NULL
to	NULL
each	NULL
well	NULL
and	NULL
incubated	NULL
for	NULL
1	NULL
h.	NULL
The	NULL
wells	NULL
were	NULL
washed	NULL
again	NULL
followed	NULL
by	NULL
addition	NULL
of	NULL
the	NULL
developing	NULL
solution	NULL
(	NULL
0.1	NULL
%	NULL
hydrogen	NULL
peroxide	NULL
[	NULL
30	NULL
%	NULL
]	NULL
and	NULL
400	NULL
ug	NULL
ml~	NULL
'	NULL
o-phenyle-nediamine	NULL
dihydrochloride	NULL
in	NULL
citrate	NULL
phosphate	NULL
buffer	NULL
[	NULL
0.15	NULL
M	NULL
;	NULL
pH	NULL
5.0	NULL
]	NULL
)	NULL
to	NULL
each	NULL
well	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
terminated	NULL
after	NULL
20	NULL
min	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
25	NULL
%	NULL
sulphuric	NULL
acid	NULL
(	NULL
25	NULL
ul	NULL
)	NULL
and	NULL
the	NULL
optical	NULL
density	NULL
determined	NULL
using	NULL
an	NULL
automated	NULL
microplate	NULL
reader	NULL
(	NULL
Dynatech	NULL
MR	NULL
600	NULL
,	NULL
Guernsey	NULL
,	NULL
U.K.	NULL
)	NULL
at	NULL
an	NULL
absorbance	NULL
of	NULL
490	NULL
nm	NULL
.	NULL

Haptenation	NULL
of	NULL
human	NULL
white	NULL
blood	NULL
cells	NULL
by	NULL
sulphamethoxazole	NULL
,	NULL
sulphamethoxazole	NULL
hydroxylamine	NULL
and	NULL
nitroso	NULL
sulphamethoxazole	NULL
Neutrophils	NULL
or	NULL
lymphocytes	NULL
(	NULL
1x	NULL
10®	NULL
ml-	NULL
'	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
or	NULL
SMX-NO	NULL
(	NULL
1-1000	NULL
um	NULL
)	NULL
in	NULL
PBS	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
GSH	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
control	NULL
incubations	NULL
contained	NULL
the	NULL
vehicle	NULL
(	NULL
DMSO	NULL
)	NULL
only	NULL
.	NULL

In	NULL
other	NULL
experiments	NULL
,	NULL
SMX	NULL
(	NULL
2.5	NULL
mM	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
neutrophils	NULL
(	NULL
1x10	NULL
'	NULL
ml-	NULL
'	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PMA	NULL
(	NULL
10	NULL
ng	NULL
ml-	NULL
'	NULL
)	NULL
,	NULL
a	NULL
cell	NULL
activating	NULL
factor	NULL
(	NULL
Thompson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Antigen	NULL
formation	NULL
on	NULL
cell	NULL
surfaces	NULL
from	NULL
SMX	NULL
or	NULL
its	NULL
metabolites	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
as	NULL
follows	NULL
.	NULL

The	NULL
drug	NULL
or	NULL
vehicle-treated	NULL
control	NULL
cells	NULL
(	NULL
1x	NULL
10°	NULL
)	NULL
were	NULL
washed	NULL
(	NULL
3	NULL
x	NULL
1	NULL
ml	NULL
)	NULL
in	NULL
ice-cold	NULL
PBS	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
and	NULL
centrifuged	NULL
(	NULL
1100	NULL
x	NULL
g	NULL
)	NULL
prior	NULL
to	NULL
incubation	NULL
with	NULL
anti-SMX	NULL
IgG	NULL
antibody	NULL
(	NULL
1:500	NULL
,	NULL
40	NULL
ul	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
(	NULL
0.5	NULL
ml	NULL
)	NULL
to	NULL
remove	NULL
unconjugated	NULL
anti-SMX	NULL
antibody	NULL
,	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
FITC-conjugated	NULL
anti-IgG	NULL
antibody	NULL
(	NULL
1:50	NULL
,	NULL
40	NULL
wl	NULL
)	NULL
for	NULL
a	NULL
further	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

After	NULL
antibody	NULL
labelling	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
PBS	NULL
and	NULL
kept	NULL
on	NULL
ice	NULL
prior	NULL
to	NULL
analysis	NULL
using	NULL
an	NULL
EPICS-XL	NULL
flow	NULL
cytometer	NULL
(	NULL
Coulter	NULL
Electronics	NULL
,	NULL
Luton	NULL
,	NULL
Beds	NULL
.	NULL

,	NULL
U.K.	NULL
)	NULL
.	NULL

The	NULL
fluorescence	NULL
threshold	NULL
gating	NULL
was	NULL
set	NULL
to	NULL
give	NULL
<	NULL
5	NULL
%	NULL
positive	NULL
cells	NULL
in	NULL
the	NULL
negative	NULL
control	NULL
populations	NULL
.	NULL

Greater	NULL
than	NULL
3000	NULL
cells	NULL
per	NULL
sample	NULL
were	NULL
analysed	NULL
in	NULL
each	NULL
case	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
cells	NULL
staining	NULL
positively	NULL
for	NULL
SMX	NULL
was	NULL
then	NULL
calculated	NULL
as	NULL
the	NULL
difference	NULL
from	NULL
the	NULL
negative	NULL
controls	NULL
.	NULL

Assessment	NULL
of	NULL
white	NULL
and	NULL
red	NULL
blood	NULL
cell	NULL
toxicity	NULL
of	NULL
sulphamethoxazole	NULL
and	NULL
its	NULL
hydroxylamine	NULL
and	NULL
nitroso	NULL
metabolites	NULL
Neutrophil	NULL
and	NULL
lymphocyte	NULL
membrane	NULL
integrity	NULL
was	NULL
assessed	NULL
by	NULL
trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Pirmohamed	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
with	NULL
SMX	NULL
,	NULL
D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
1395	NULL
SMX-NHOH	NULL
or	NULL
SMX-NO	NULL
(	NULL
1-1000	NULL
um	NULL
)	NULL
in	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
(	NULL
1	NULL
ml	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
in	NULL
a	NULL
shaking	NULL
water	NULL
bath	NULL
at	NULL
37°C	NULL
for	NULL
1	NULL
h.	NULL
Data	NULL
represents	NULL
the	NULL
percentage	NULL
of	NULL
trypan	NULL
blue	NULL
stained	NULL
cells/total	NULL
number	NULL
of	NULL
cells	NULL
.	NULL

Apoptosis	NULL
and	NULL
necrosis	NULL
are	NULL
morphologically	NULL
distinct	NULL
modes	NULL
of	NULL
cell	NULL
death	NULL
(	NULL
Searle	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

While	NULL
apoptosis	NULL
occurs	NULL
prior	NULL
to	NULL
and	NULL
at	NULL
lower	NULL
toxicant	NULL
dose	NULL
than	NULL
necrotic	NULL
cell	NULL
death	NULL
(	NULL
Raffray	NULL
&	NULL
Cohen	NULL
,	NULL
1997	NULL
)	NULL
,	NULL
cell	NULL
selectivity	NULL
of	NULL
toxicants	NULL
can	NULL
stem	NULL
from	NULL
the	NULL
apoptotic	NULL
and	NULL
necrotic	NULL
thresholds	NULL
at	NULL
which	NULL
different	NULL
cells	NULL
die	NULL
,	NULL
site	NULL
of	NULL
bioactivation/detoxification	NULL
or	NULL
site	NULL
of	NULL
toxicant	NULL
accumulation	NULL
.	NULL

For	NULL
these	NULL
reasons	NULL
,	NULL
lymphocyte	NULL
and	NULL
neutrophil	NULL
apoptosis	NULL
was	NULL
quantified	NULL
morphologically	NULL
and	NULL
by	NULL
flow	NULL
cytometry	NULL
at	NULL
lower	NULL
concentrations	NULL
than	NULL
that	NULL
required	NULL
to	NULL
cause	NULL
necrotic	NULL
cell	NULL
death	NULL
.	NULL

Cells	NULL
(	NULL
1	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
or	NULL
SMX-NO	NULL
(	NULL
1-300	NULL
uM	NULL
)	NULL
in	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
.	NULL

Drugs	NULL
were	NULL
added	NULL
in	NULL
DMSO	NULL
,	NULL
which	NULL
as	NULL
a	NULL
1	NULL
%	NULL
solution	NULL
(	NULL
v¥v-	NULL
'	NULL
)	NULL
did	NULL
not	NULL
induce	NULL
apoptosis	NULL
.	NULL

Some	NULL
incubations	NULL
also	NULL
contained	NULL
GSH	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
.	NULL

After	NULL
2	NULL
h	NULL
,	NULL
the	NULL
tubes	NULL
were	NULL
centrifuged	NULL
(	NULL
650	NULL
xg	NULL
;	NULL
10	NULL
min	NULL
)	NULL
to	NULL
pellet	NULL
the	NULL
cells	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
discarded	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
drug-free	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
containing	NULL
human	NULL
serum	NULL
-	NULL
albumin	NULL
(	NULL
5	NULL
mg	NULL
ml-	NULL
'	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
incubated	NULL
for	NULL
a	NULL
further	NULL
6	NULL
h	NULL
prior	NULL
to	NULL
analysis	NULL
.	NULL

Cells	NULL
were	NULL
assessed	NULL
for	NULL
characteristic	NULL
morphologic	NULL
changes	NULL
using	NULL
Wright	NULL
's	NULL
stain	NULL
.	NULL

Stained	NULL
cells	NULL
were	NULL
viewed	NULL
under	NULL
a	NULL
light	NULL
microscope	NULL
(	NULL
Shandon	NULL
Elliot	NULL
,	NULL
London	NULL
,	NULL
U.K.	NULL
)	NULL
for	NULL
apoptotic	NULL
structure	NULL
(	NULL
Watson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996b	NULL
)	NULL
.	NULL

At	NULL
least	NULL
200	NULL
cells	NULL
were	NULL
examined	NULL
.	NULL

Flow	NULL
cytometric	NULL
evaluation	NULL
of	NULL
apoptotic	NULL
was	NULL
assessed	NULL
according	NULL
to	NULL
the	NULL
method	NULL
originally	NULL
described	NULL
by	NULL
Nicoletti	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
(	NULL
200	NULL
x	NULL
g	NULL
;	NULL
8	NULL
min	NULL
)	NULL
,	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
70	NULL
%	NULL
ethanol	NULL
(	NULL
v	NULL
v~-	NULL
'	NULL
)	NULL
and	NULL
stored	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
fixed	NULL
cell	NULL
suspensions	NULL
were	NULL
then	NULL
centrifuged	NULL
,	NULL
washed	NULL
with	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
(	NULL
1	NULL
ml	NULL
)	NULL
and	NULL
finally	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
hypotonic	NULL
fluorochrome	NULL
solution	NULL
(	NULL
propidium	NULL
iodide	NULL
,	NULL
50	NULL
ug	NULL
ml~	NULL
'	NULL
;	NULL
sodium	NULL
citrate	NULL
,	NULL
3.4	NULL
mM	NULL
;	NULL
Tris	NULL
,	NULL
1	NULL
mM	NULL
;	NULL
EDTA	NULL
,	NULL
100	NULL
uM	NULL
;	NULL
RNAse	NULL
[	NULL
type	NULL
I-Al	NULL
,	NULL
500	NULL
ug	NULL
ml-	NULL
'	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
kept	NULL
overnight	NULL
in	NULL
the	NULL
dark	NULL
(	NULL
4°C	NULL
)	NULL
prior	NULL
to	NULL
FACScan	NULL
analysis	NULL
on	NULL
a	NULL
Becton	NULL
Dickinson	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
CA	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Propidium	NULL
iodide	NULL
fluorescence	NULL
(	NULL
FL-2	NULL
)	NULL
of	NULL
individual	NULL
nuclei	NULL
was	NULL
registered	NULL
on	NULL
a	NULL
logarithmic	NULL
scale	NULL
.	NULL

At	NULL
least	NULL
5000	NULL
nuclei	NULL
were	NULL
counted	NULL
and	NULL
analysed	NULL
on	NULL
a	NULL
Hewlett	NULL
Packard	NULL
(	NULL
HP	NULL
9000	NULL
)	NULL
computer	NULL
using	NULL
Lysis	NULL
II	NULL
software	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
(	NULL
1-300	NULL
uM	NULL
)	NULL
to	NULL
inhibit	NULL
the	NULL
neutrophil	NULL
oxidative	NULL
burst	NULL
was	NULL
determined	NULL
using	NULL
the	NULL
nitroblue	NULL
tetrazolium	NULL
slide	NULL
test	NULL
and	NULL
an	NULL
indirect	NULL
procedure	NULL
that	NULL
involves	NULL
inhibition	NULL
of	NULL
eugenol-induced	NULL
GSH	NULL
depletion	NULL
by	NULL
the	NULL
test	NULL
compounds	NULL
.	NULL

The	NULL
experimental	NULL
protocols	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
Naisbitt	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Red	NULL
blood	NULL
cell	NULL
toxicity	NULL
was	NULL
assessed	NULL
by	NULL
measuring	NULL
the	NULL
amount	NULL
of	NULL
methaemoglobin	NULL
(	NULL
MetHb	NULL
)	NULL
formed	NULL
when	NULL
cells	NULL
(	NULL
50	NULL
%	NULL
haematocrit	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
,	NULL
according	NULL
to	NULL
the	NULL
method	NULL
of	NULL
Harrison	NULL
&	NULL
Jollow	NULL
(	NULL
1986	NULL
)	NULL
.	NULL

Determination	NULL
of	NULL
NF-KB	NULL
and	NULL
AP-1	NULL
levels	NULL
in	NULL
lymphocytes	NULL
Freshly	NULL
isolated	NULL
lymphocytes	NULL
were	NULL
incubated	NULL
in	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
glutamine	NULL
(	NULL
2	NULL
mM	NULL
)	NULL
and	NULL
penicillin	NULL
(	NULL
50	NULL
units	NULL
ml~	NULL
``	NULL
)	NULL
/streptomycin	NULL
(	NULL
50	NULL
ug	NULL
ml-	NULL
'	NULL
)	NULL
at	NULL
a	NULL
density	NULL
of	NULL
1-3	NULL
x	NULL
10°	NULL
cells	NULL
ml-	NULL
'	NULL
.	NULL

After	NULL
24	NULL
h	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
SMX-NO	NULL
(	NULL
1-1000	NULL
um	NULL
)	NULL
for	NULL
a	NULL
further	NULL
1	NULL
h	NULL
in	NULL
cell	NULL
culture	NULL
tubes	NULL
(	NULL
37°C	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
)	NULL
.	NULL

NF-xB	NULL
and	NULL
AP-1	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
determined	NULL
using	NULL
the	NULL
Promega	NULL
Gel	NULL
Shift	NULL
Assay	NULL
System	NULL
(	NULL
Promega	NULL
,	NULL
Southampton	NULL
,	NULL
U.K.	NULL
)	NULL
.	NULL

The	NULL
double	NULL
stranded	NULL
DNA	NULL
oligonucleotide	NULL
probes	NULL
used	NULL
contained	NULL
the	NULL
following	NULL
sequences	NULL
:	NULL
NF-KB	NULL
5-AGT	NULL
TGA	NULL
GGG	NULL
GAC	NULL
TTT	NULL
CCC	NULL
AGG	NULL
C-3	NULL
'	NULL
AP-1	NULL
5-CGC	NULL
TTG	NULL
ATG	NULL
AGT	NULL
CAG	NULL
CCG	NULL
GTA	NULL
A-3	NULL
'	NULL
Oligonucleotide	NULL
probes	NULL
were	NULL
[	NULL
y-P	NULL
]	NULL
-ATP	NULL
(	NULL
Amersham	NULL
International	NULL
,	NULL
Amersham	NULL
,	NULL
U.K.	NULL
)	NULL
end-labelled	NULL
with	NULL
T4	NULL
poly-nucleotide	NULL
kinase	NULL
.	NULL

Binding	NULL
reactions	NULL
consisted	NULL
of	NULL
nuclear	NULL
protein	NULL
(	NULL
2	NULL
ug	NULL
)	NULL
,	NULL
5x	NULL
binding	NULL
buffer	NULL
and	NULL
labelled	NULL
NF-xB	NULL
or	NULL
AP-1	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
50,000	NULL
c.p.m	NULL
.	NULL
)	NULL

.	NULL

Competitive	NULL
mobility	NULL
shift	NULL
reactions	NULL
included	NULL
unlabelled	NULL
NF-xB	NULL
or	NULL
AP-1	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
1.75	NULL
pmol	NULL
)	NULL
to	NULL
characterize	NULL
the	NULL
DNA	NULL
binding	NULL
specificity	NULL
.	NULL

Following	NULL
incubation	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
samples	NULL
were	NULL
loaded	NULL
onto	NULL
a	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
and	NULL
electrophoresis	NULL
was	NULL
performed	NULL
at	NULL
150	NULL
V	NULL
for	NULL
2.5	NULL
h.	NULL
The	NULL
gels	NULL
were	NULL
then	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
photographic	NULL
film	NULL
.	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
integrated	NULL
optical	NULL
density	NULL
of	NULL
each	NULL
band	NULL
.	NULL

All	NULL
experiments	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
cells	NULL
from	NULL
three	NULL
individuals	NULL
.	NULL

Reaction	NULL
of	NULL
sulphamethoxazole	NULL
,	NULL
sulphamethoxazole	NULL
hydroxylamine	NULL
and	NULL
nitroso	NULL
sulphamethoxazole	NULL
with	NULL
biological	NULL
thiols	NULL
To	NULL
determine	NULL
the	NULL
relative	NULL
importance	NULL
of	NULL
intracellular	NULL
and	NULL
extracellular	NULL
thiols	NULL
in	NULL
the	NULL
detoxification	NULL
of	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
,	NULL
we	NULL
investigated	NULL
their	NULL
reaction	NULL
with	NULL
CYS	NULL
(	NULL
the	NULL
most	NULL
abundant	NULL
extracellular	NULL
thiol	NULL
in	NULL
plasma	NULL
;	NULL
Eck	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
and	NULL
compared	NULL
it	NULL
to	NULL
their	NULL
reaction	NULL
with	NULL
GSH	NULL
(	NULL
a	NULL
predominantly	NULL
intracellular	NULL
thiol	NULL
)	NULL
,	NULL
which	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
Cribb	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

SMX	NULL
(	NULL
50	NULL
um	NULL
)	NULL
or	NULL
its	NULL
metabolites	NULL
(	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
;	NULL
50	NULL
uM	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
CYS	NULL
(	NULL
100	NULL
um	NULL
)	NULL
in	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
(	NULL
1	NULL
ml	NULL
)	NULL
at	NULL
37°C	NULL
for	NULL
0.2	NULL
,	NULL
1	NULL
,	NULL
8	NULL
or	NULL
20	NULL
h.	NULL
Aliquots	NULL
(	NULL
25	NULL
ul	NULL
)	NULL
of	NULL
the	NULL
reaction	NULL
mixture	NULL
were	NULL
analysed	NULL
at	NULL
each	NULL
time-point	NULL
by	NULL
LC-MS	NULL
,	NULL
using	NULL
a	NULL
previously	NULL
described	NULL
protocol	NULL
(	NULL
Gill	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

SMX	NULL
and	NULL
SMX-NHOH	NULL
were	NULL
identified	NULL
from	NULL
authentic	NULL
standards	NULL
,	NULL
whereas	NULL
any	NULL
reaction	NULL
intermediates	NULL
were	NULL
identified	NULL
from	NULL
their	NULL
parent	NULL
molecular	NULL
ion	NULL
peak	NULL
and	NULL
retention	NULL
times	NULL
quoted	NULL
previously	NULL
(	NULL
Naisbitt	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

1.2	NULL
-	NULL
[	NULL
]	NULL
Suiphamethoxazole	NULL
7	NULL
B	NULL
Sulphamethoxazole	NULL
1.0	NULL
-	NULL
hydroxylamine	NULL
f=	NULL
F	NULL
Nitroso	NULL
c	NULL
&	NULL
os	NULL
-	NULL
sulphamethoxazole	NULL
u	NULL
TL	NULL
8	NULL
0.6	NULL
fe	NULL
G	NULL
2	NULL
9	NULL
0.4	NULL
-	NULL
x	NULL
Q	NULL
*	NULL
<	NULL
U	NULL
__m	NULL
1	NULL
0	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
Concentration	NULL
(	NULL
uM	NULL
)	NULL
Figure	NULL
1	NULL
-	NULL
Haptenation	NULL
of	NULL
thiolated	NULL
human	NULL
serum	NULL
albumin	NULL
by	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
or	NULL
SMX-NO	NULL
(	NULL
1-1000	NULL
um	NULL
)	NULL
after	NULL
a	NULL
24	NULL
h	NULL
incubation	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
absorbance	NULL
above	NULL
the	NULL
background	NULL
values	NULL
for	NULL
three	NULL
experiments	NULL
.	NULL

Statistical	NULL
analysis	NULL
performed	NULL
by	NULL
comparing	NULL
the	NULL
relative	NULL
absorbance	NULL
at	NULL
different	NULL
concentrations	NULL
of	NULL
the	NULL
compounds	NULL
with	NULL
that	NULL
of	NULL
the	NULL
control	NULL
value	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

1396	NULL
D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
Two	NULL
major	NULL
difficulties	NULL
were	NULL
encountered	NULL
with	NULL
the	NULL
use	NULL
of	NULL
LC-MS.	NULL
Firstly	NULL
,	NULL
the	NULL
concentration	NULL
of	NULL
SMX-NO	NULL
throughout	NULL
the	NULL
reaction	NULL
could	NULL
not	NULL
be	NULL
measured	NULL
because	NULL
it	NULL
only	NULL
produces	NULL
a	NULL
very	NULL
weak	NULL
protonated	NULL
molecule	NULL
;	NULL
and	NULL
second	NULL
,	NULL
absolute	NULL
quantification	NULL
of	NULL
the	NULL
amounts	NULL
of	NULL
products	NULL
formed	NULL
is	NULL
not	NULL
possible	NULL
.	NULL

To	NULL
overcome	NULL
these	NULL
problems	NULL
,	NULL
the	NULL
reactions	NULL
of	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
(	NULL
10	NULL
mm	NULL
)	NULL
with	NULL
CYS	NULL
in	NULL
d	NULL
,	NULL
-DMSO	NULL
were	NULL
analysed	NULL
by	NULL
proton	NULL
NMR	NULL
.	NULL

DMSO	NULL
as	NULL
a	NULL
solvent	NULL
has	NULL
the	NULL
added	NULL
advantage	NULL
of	NULL
stabilizing	NULL
SMX-NHOH	NULL
,	NULL
thus	NULL
allowing	NULL
the	NULL
analysis	NULL
of	NULL
reaction	NULL
intermediates	NULL
over	NULL
a	NULL
longer	NULL
time	NULL
period	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
96	NULL
h	NULL
;	NULL
Naisbitt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
each	NULL
intermediate	NULL
formed	NULL
was	NULL
quantified	NULL
by	NULL
measurement	NULL
of	NULL
the	NULL
integral	NULL
peak	NULL
height	NULL
from	NULL
each	NULL
spectrum	NULL
throughout	NULL
the	NULL
reaction	NULL
period	NULL
.	NULL

All	NULL
reaction	NULL
intermediates	NULL
were	NULL
identified	NULL
from	NULL
NMR	NULL
spectra	NULL
of	NULL
standard	NULL
compounds	NULL
.	NULL

The	NULL
reactions	NULL
of	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
with	NULL
CYS	NULL
and	NULL
GSH	NULL
were	NULL
also	NULL
determined	NULL
by	NULL
fluorescence	NULL
HPLC	NULL
.	NULL

a	NULL
Lymphocytes	NULL
75	NULL
65	NULL
55	NULL
-|	NULL
45	NULL
35	NULL
-I	NULL
25	NULL
15	NULL
-	NULL
+	NULL
Positively	NULL
stained	NULL
cells	NULL
(	NULL
%	NULL
)	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
SMX-NHOH	NULL
(	NULL
uM	NULL
)	NULL
The	NULL
compounds	NULL
(	NULL
1-300	NULL
um	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
either	NULL
CYS	NULL
or	NULL
GSH	NULL
(	NULL
3	NULL
um	NULL
)	NULL
in	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
(	NULL
1	NULL
ml	NULL
)	NULL
at	NULL
37°C	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Free	NULL
sulphydryl	NULL
groups	NULL
were	NULL
measured	NULL
as	NULL
described	NULL
previously	NULL
,	NULL
using	NULL
the	NULL
fluorescent	NULL
probe	NULL
bromobimane	NULL
(	NULL
Cotgreave	NULL
&	NULL
Moldeus	NULL
,	NULL
1986	NULL
;	NULL
Pirmohamed	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
reaction	NULL
between	NULL
SMX-NO	NULL
(	NULL
30	NULL
um	NULL
)	NULL
and	NULL
a	NULL
mixture	NULL
of	NULL
CYS	NULL
(	NULL
10	NULL
um	NULL
)	NULL
and	NULL
GSH	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
in	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
was	NULL
analysed	NULL
by	NULL
a	NULL
similar	NULL
method	NULL
.	NULL

Incubations	NULL
were	NULL
carried	NULL
out	NULL
at	NULL
37°C	NULL
and	NULL
thiol	NULL
levels	NULL
were	NULL
measured	NULL
at	NULL
intervals	NULL
between	NULL
0-60	NULL
min	NULL
.	NULL

Depletion	NULL
of	NULL
glutathione	NULL
and	NULL
cysteine	NULL
from	NULL
neutrophils	NULL
,	NULL
lymphocytes	NULL
and	NULL
plasma	NULL
Intact	NULL
or	NULL
lysed	NULL
peripheral	NULL
white	NULL
blood	NULL
cells	NULL
(	NULL
0.5	NULL
x	NULL
10°	NULL
cells/	NULL
incubation	NULL
)	NULL
were	NULL
incubated	NULL
(	NULL
final	NULL
volume	NULL
1	NULL
ml	NULL
)	NULL
in	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
at	NULL
37°C	NULL
for	NULL
1	NULL
h	NULL
with	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
or	NULL
SMX-NO	NULL
(	NULL
1	NULL
400	NULL
um	NULL
)	NULL
.	NULL

The	NULL
experiments	NULL
with	NULL
neutrophils	NULL
were	NULL
performed	NULL
both	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
PMA	NULL
(	NULL
10	NULL
ng	NULL
ml-	NULL
'	NULL
)	NULL
.	NULL

PMA	NULL
75	NULL
___|	NULL
65	NULL
5§	NULL
45	NULL
Positively	NULL
stained	NULL
cells	NULL
(	NULL
%	NULL
)	NULL
G	NULL
l	NULL
1	NULL
g	NULL
untreated	NULL
I	NULL
+1imM	NULL
GSH	NULL
b	NULL
Neutrophils	NULL
75	NULL
65	NULL
55	NULL
-I	NULL
45	NULL
35	NULL
25	NULL
$	NULL
.	NULL

‘	NULL
lL	NULL
5	NULL
T	NULL
-	NULL
C5	NULL
+	NULL
L	NULL
10	NULL
100	NULL
SMX-NHOH	NULL
(	NULL
uM	NULL
)	NULL
Positively	NULL
stained	NULL
cells	NULL
(	NULL
%	NULL
)	NULL
l	NULL
1000	NULL
25	NULL
15	NULL
-	NULL
L	NULL
5	NULL
-	NULL
I	NULL
s	NULL
0	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
SMX-NO	NULL
(	NULL
uM	NULL
)	NULL
75	NULL
g	NULL
65	NULL
&	NULL
55	NULL
©	NULL
O	NULL
u	NULL
45	NULL
®	NULL
2	NULL
+	NULL
@	NULL
3s	NULL
#	NULL
T	NULL
2s	NULL
$	NULL
.	NULL

C	NULL
15	NULL
-	NULL
.	NULL

t	NULL
[	NULL
al	NULL
1	NULL
L	NULL
ae	NULL
14	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
SMX-NO	NULL
(	NULL
uM	NULL
)	NULL
Figure	NULL
2	NULL
-	NULL
Haptenation	NULL
of	NULL
lymphocytes	NULL
(	NULL
a	NULL
)	NULL
and	NULL
neutrophils	NULL
(	NULL
b	NULL
)	NULL
after	NULL
incubation	NULL
with	NULL
either	NULL
SMX-NHOH	NULL
or	NULL
SMX-NO	NULL
for	NULL
1	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
GSH	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
.	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
positively	NULL
stained	NULL
cells	NULL
from	NULL
four	NULL
experiments	NULL
.	NULL

Statistical	NULL
analysis	NULL
compares	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
drugs	NULL
to	NULL
haptenate	NULL
cells	NULL
with	NULL
that	NULL
of	NULL
the	NULL
control	NULL
value	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
and	NULL
the	NULL
effect	NULL
of	NULL
GSH	NULL
on	NULL
cellular	NULL
staining	NULL
at	NULL
each	NULL
drug	NULL
concentration	NULL
(	NULL
{	NULL
P	NULL
?	NULL

<	NULL
0.05	NULL
)	NULL
.	NULL

D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
1397	NULL
stimulates	NULL
the	NULL
neutrophil	NULL
respiratory	NULL
burst	NULL
,	NULL
a	NULL
phenomena	NULL
known	NULL
to	NULL
oxidize	NULL
almost	NULL
any	NULL
compound	NULL
with	NULL
an	NULL
easily	NULL
oxidizable	NULL
functional	NULL
group	NULL
(	NULL
Uetrecht	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

Protein	NULL
was	NULL
precipitated	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
100	NULL
%	NULL
trichloroacetic	NULL
acid	NULL
(	NULL
10	NULL
wl	NULL
)	NULL
and	NULL
thiol	NULL
levels	NULL
were	NULL
measured	NULL
using	NULL
bromobimane	NULL
(	NULL
Cotgreave	NULL
&	NULL
Moldeus	NULL
,	NULL
1986	NULL
;	NULL
Pirmohamed	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Plasma	NULL
thiol	NULL
depletion	NULL
was	NULL
analysed	NULL
by	NULL
a	NULL
similar	NULL
method	NULL
except	NULL
that	NULL
1	NULL
ml	NULL
of	NULL
ice-cold	NULL
plasma	NULL
was	NULL
added	NULL
to	NULL
each	NULL
incubation	NULL
instead	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

The	NULL
basal	NULL
levels	NULL
of	NULL
the	NULL
thiols	NULL
were	NULL
measured	NULL
prior	NULL
to	NULL
the	NULL
incubation	NULL
and	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
any	NULL
of	NULL
the	NULL
compounds	NULL
.	NULL

Additionally	NULL
,	NULL
thiol	NULL
stability	NULL
after	NULL
isolation	NULL
of	NULL
the	NULL
plasma	NULL
and	NULL
cells	NULL
was	NULL
assessed	NULL
between	NULL
0-5	NULL
h.	NULL
The	NULL
results	NULL
are	NULL
presented	NULL
as	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
separate	NULL
incubations	NULL
conducted	NULL
in	NULL
triplicate	NULL
.	NULL

GSH	NULL
and	NULL
CYS	NULL
standard	NULL
curves	NULL
were	NULL
constructed	NULL
between	NULL
0.5	NULL
and	NULL
50	NULL
um	NULL
.	NULL

Reduction	NULL
of	NULL
sulphamethoxazole	NULL
hydroxylamine	NULL
and	NULL
nitroso	NULL
sulphamethoxazole	NULL
by	NULL
the	NULL
individual	NULL
components	NULL
of	NULL
peripheral	NULL
blood	NULL
Isolated	NULL
neutrophils	NULL
,	NULL
lymphocytes	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
)	NULL
and	NULL
plasma	NULL
(	NULL
1	NULL
ml	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
(	NULL
30	NULL
um	NULL
)	NULL
in	NULL
a	NULL
shaking	NULL
water	NULL
bath	NULL
at	NULL
37°C	NULL
in	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
.	NULL

The	NULL
neutrophil	NULL
incubations	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
PMA	NULL
(	NULL
10	NULL
ng	NULL
ml-	NULL
'	NULL
)	NULL
.	NULL

After	NULL
1	NULL
h	NULL
,	NULL
the	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
placing	NULL
the	NULL
tubes	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
internal	NULL
standard	NULL
,	NULL
dapsone	NULL
(	NULL
5	NULL
uM	NULL
)	NULL
,	NULL
was	NULL
added	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
neutrophils	NULL
were	NULL
lysed	NULL
by	NULL
repeated	NULL
freeze	NULL
thawing	NULL
.	NULL

Extraction	NULL
was	NULL
performed	NULL
with	NULL
ethyl	NULL
acetate	NULL
(	NULL
2x3	NULL
ml	NULL
)	NULL
.	NULL

The	NULL
combined	NULL
extracts	NULL
were	NULL
evaporated	NULL
to	NULL
dryness	NULL
under	NULL
nitrogen	NULL
,	NULL
reconstituted	NULL
in	NULL
mobile	NULL
phase	NULL
(	NULL
100	NULL
wl	NULL
)	NULL
and	NULL
analysed	NULL
by	NULL
HPLC	NULL
using	NULL
the	NULL
system	NULL
described	NULL
above	NULL
.	NULL

Further	NULL
experiments	NULL
were	NULL
carried	NULL
out	NULL
to	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
nitroso	NULL
reductase	NULL
enzymes	NULL
in	NULL
the	NULL
reduction	NULL
of	NULL
SMX-NO	NULL
.	NULL

Neutrophils	NULL
(	NULL
5	NULL
x	NULL
10°-5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
SMX-NO	NULL
(	NULL
30	NULL
um	NULL
)	NULL
in	NULL
a	NULL
shaking	NULL
water	NULL
bath	NULL
at	NULL
37°C	NULL
in	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
for	NULL
1	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
reductase	NULL
inhibitors	NULL
salicyl	NULL
hydroxamate	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
,	NULL
dicuomarol	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
,	NULL
neocuproin	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
,	NULL
or	NULL
sodium	NULL
azide	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
(	NULL
Somerville	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

SMX-NHOH	NULL
and	NULL
SMX	NULL
formation	NULL
was	NULL
measured	NULL
by	NULL
HPLC	NULL
.	NULL

Incubations	NULL
containing	NULL
red	NULL
blood	NULL
cells	NULL
(	NULL
0.5	NULL
ml	NULL
,	NULL
50	NULL
%	NULL
haematocrit	NULL
)	NULL
and	NULL
SMX-NHOH	NULL
(	NULL
1-100	NULL
um	NULL
)	NULL
or	NULL
SMX-NO	NULL
(	NULL
30	NULL
um	NULL
)	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
above	NULL
and	NULL
terminated	NULL
after	NULL
1	NULL
h	NULL
by	NULL
placing	NULL
the	NULL
tubes	NULL
on	NULL
ice	NULL
.	NULL

Internal	NULL
standard	NULL
was	NULL
added	NULL
to	NULL
the	NULL
samples	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
lysed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
0.5	NULL
ml	NULL
distilled	NULL
water	NULL
.	NULL

Following	NULL
extraction	NULL
with	NULL
ethyl	NULL
acetate	NULL
(	NULL
2	NULL
x	NULL
3	NULL
ml	NULL
)	NULL
,	NULL
the	NULL
samples	NULL
were	NULL
reconstituted	NULL
in	NULL
mobile	NULL
phase	NULL
(	NULL
100	NULL
ul	NULL
)	NULL
and	NULL
analysed	NULL
by	NULL
HPLC	NULL
.	NULL

SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
were	NULL
also	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
in	NULL
either	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
,	NULL
ethyl	NULL
acetate	NULL
or	NULL
mobile	NULL
phase	NULL
(	NULL
37°C	NULL
)	NULL
,	NULL
and	NULL
analysed	NULL
by	NULL
HPLC	NULL
to	NULL
measure	NULL
any	NULL
spontaneous	NULL
reduction	NULL
.	NULL

All	NULL
incubations	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
using	NULL
cells	NULL
from	NULL
four	NULL
individuals	NULL
.	NULL

Red	NULL
blood	NULL
cell	NULL
accumulation	NULL
of	NULL
sulphamethoxazole	NULL
hydroxylamine	NULL
and	NULL
dapsone	NULL
hydroxylamine	NULL
Freshly	NULL
drawn	NULL
blood	NULL
from	NULL
healthy	NULL
volunteers	NULL
was	NULL
collected	NULL
into	NULL
potassium-EDTA	NULL
tubes	NULL
containing	NULL
GSH	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
.	NULL

GSH	NULL
was	NULL
added	NULL
to	NULL
stabilize	NULL
the	NULL
hydroxylamine	NULL
and	NULL
prevent	NULL
auto-oxidation	NULL
to	NULL
the	NULL
nitroso	NULL
metabolite	NULL
(	NULL
Mitra	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

SMX-NHOH	NULL
(	NULL
10	NULL
um	NULL
)	NULL
or	NULL
dapsone	NULL
hydroxylamine	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
blood	NULL
(	NULL
0.5	NULL
ml	NULL
)	NULL
at	NULL
37°C	NULL
for	NULL
various	NULL
times	NULL
(	NULL
10	NULL
,	NULL
20	NULL
,	NULL
40	NULL
,	NULL
60	NULL
and	NULL
100	NULL
min	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
then	NULL
microcentrifuged	NULL
for	NULL
1	NULL
min	NULL
(	NULL
13,000	NULL
xg	NULL
)	NULL
and	NULL
an	NULL
aliquot	NULL
of	NULL
the	NULL
plasma	NULL
was	NULL
removed	NULL
into	NULL
a	NULL
silanized	NULL
glass	NULL
tube	NULL
into	NULL
which	NULL
the	NULL
internal	NULL
standard	NULL
[	NULL
SMX	NULL
(	NULL
5	NULL
uM	NULL
)	NULL
for	NULL
dapsone	NULL
hydroxylamine	NULL
incubations	NULL
and	NULL
dapsone	NULL
(	NULL
5	NULL
uM	NULL
)	NULL
for	NULL
SMX-NHOH	NULL
incubations	NULL
]	NULL
was	NULL
added	NULL
.	NULL

Extraction	NULL
was	NULL
performed	NULL
using	NULL
ethyl	NULL
acetate	NULL
(	NULL
2	NULL
x	NULL
3	NULL
ml	NULL
)	NULL
.	NULL

The	NULL
solvent	NULL
was	NULL
evaporated	NULL
to	NULL
dryness	NULL
and	NULL
samples	NULL
were	NULL
reconstituted	NULL
in	NULL
methanol	NULL
:	NULL
distilled	NULL
water	NULL
(	NULL
1:1	NULL
vyv~	NULL
'	NULL
)	NULL
containing	NULL
GSH	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
,	NULL
and	NULL
analysed	NULL
using	NULL
HPLC	NULL
with	NULL
UV	NULL
(	NULL
Gill	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
and	NULL
electrochemical	NULL
detection	NULL
(	NULL
Antdec	NULL
Decade	NULL
Electrochemical	NULL
Detector	NULL
,	NULL
Protech	NULL
Scientific	NULL
Ltd	NULL
,	NULL
Manchester	NULL
,	NULL
U.K.	NULL
)	NULL
.	NULL

The	NULL
limit	NULL
of	NULL
detection	NULL
was	NULL
0.025	NULL
nmole	NULL
(	NULL
dapsone	NULL
hydroxylamine	NULL
)	NULL
and	NULL
0.08	NULL
nmole	NULL
(	NULL
SMX-NHOH	NULL
)	NULL
for	NULL
UV	NULL
detection	NULL
and	NULL
1	NULL
pmole	NULL
(	NULL
dapsone	NULL
hydroxylamine	NULL
and	NULL
SMX-NHOH	NULL
)	NULL
for	NULL
electrochemical	NULL
detection	NULL
.	NULL

Inhibition	NULL
of	NULL
oxidative	NULL
burst	NULL
(	NULL
%	NULL
)	NULL
®	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
Concentration	NULL
(	NULL
uM	NULL
)	NULL
Incubation	NULL
with	NULL
:	NULL
on	NULL
©	NULL
SMX	NULL
m	NULL
SMX-NHOH	NULL
A	NULL
SMX-NO	NULL
Inhibition	NULL
of	NULL
eugenol	NULL
induced	NULL
glutathione	NULL
depletion	NULL
(	NULL
%	NULL
)	NULL
M	NULL
1	NULL
10	NULL
100	NULL
Concentration	NULL
(	NULL
uM	NULL
)	NULL
Figure	NULL
3	NULL
(	NULL
a	NULL
)	NULL
Inhibition	NULL
of	NULL
neutrophil	NULL
oxidative	NULL
metabolism	NULL
and	NULL
(	NULL
b	NULL
)	NULL
inhibition	NULL
of	NULL
eugenol-induced	NULL
GSH	NULL
depletion	NULL
in	NULL
PMA-stimulated	NULL
neutrophils	NULL
by	NULL
SMX	NULL
and	NULL
its	NULL
oxidative	NULL
metabolites	NULL
.	NULL

The	NULL
respiratory	NULL
burst	NULL
was	NULL
measured	NULL
using	NULL
the	NULL
nitroblue	NULL
tetrazolium	NULL
slide	NULL
test	NULL
.	NULL

GSH	NULL
levels	NULL
were	NULL
measured	NULL
using	NULL
bromobimane	NULL
,	NULL
by	NULL
fluorescence	NULL
HPLC	NULL
.	NULL

The	NULL
results	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
experiments	NULL
carried	NULL
out	NULL
in	NULL
triplicate	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
comparing	NULL
the	NULL
different	NULL
concentrations	NULL
of	NULL
compounds	NULL
required	NULL
to	NULL
inhibit	NULL
the	NULL
respiratory	NULL
burst	NULL
with	NULL
that	NULL
of	NULL
solvent	NULL
alone	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

1398	NULL
D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
Statistical	NULL
analysis	NULL
All	NULL
values	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
+s.d	NULL
.	NULL

All	NULL
values	NULL
to	NULL
be	NULL
compared	NULL
were	NULL
analysed	NULL
for	NULL
non-normality	NULL
using	NULL
the	NULL
Shapiro-Wilk	NULL
test	NULL
.	NULL

Values	NULL
were	NULL
often	NULL
found	NULL
to	NULL
be	NULL
non-normally	NULL
distributed	NULL
,	NULL
and	NULL
therefore	NULL
,	NULL
the	NULL
Mann-Whitney	NULL
test	NULL
was	NULL
used	NULL
for	NULL
comparison	NULL
of	NULL
the	NULL
two	NULL
groups	NULL
,	NULL
accepting	NULL
P	NULL
<	NULL
0.05	NULL
as	NULL
significant	NULL
.	NULL

Results	NULL
Haptenation	NULL
of	NULL
human	NULL
serum	NULL
albumin	NULL
by	NULL
sulphamethoxazole	NULL
and	NULL
its	NULL
metabolites	NULL
Incubation	NULL
of	NULL
human	NULL
serum	NULL
albumin	NULL
with	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
did	NULL
not	NULL
result	NULL
in	NULL
significant	NULL
binding	NULL
at	NULL
any	NULL
of	NULL
the	NULL
concentrations	NULL
tested	NULL
.	NULL

There	NULL
was	NULL
a	NULL
concentration-dependent	NULL
increase	NULL
in	NULL
binding	NULL
to	NULL
thiolated	NULL
albumin	NULL
with	NULL
both	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
,	NULL
while	NULL
SMX	NULL
itself	NULL
only	NULL
showed	NULL
binding	NULL
at	NULL
the	NULL
highest	NULL
concentration	NULL
(	NULL
1000	NULL
um	NULL
)	NULL
tested	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
cellular	NULL
haptenation	NULL
by	NULL
sulphamethoxazole	NULL
and	NULL
its	NULL
metabolites	NULL
Haptenation	NULL
of	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
to	NULL
cell	NULL
surfaces	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Incubation	NULL
of	NULL
cells	NULL
(	NULL
both	NULL
lymphocytes	NULL
and	NULL
neutrophils	NULL
)	NULL
with	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
resulted	NULL
in	NULL
a	NULL
concentration-dependent	NULL
increase	NULL
in	NULL
surface	NULL
antigen	NULL
formation	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
there	NULL
was	NULL
no	NULL
detectable	NULL
antigen	NULL
formation	NULL
when	NULL
SMX	NULL
(	NULL
1-1000	NULL
um	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
cells	NULL
.	NULL

Co-incubation	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
GSH	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
reduced	NULL
cellular	NULL
antigen	NULL
formation	NULL
at	NULL
each	NULL
concentration	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

Haptenation	NULL
to	NULL
the	NULL
surface	NULL
of	NULL
lymphocytes	NULL
on	NULL
incubation	NULL
with	NULL
SMX-NO	NULL
(	NULL
1000	NULL
um	NULL
;	NULL
52.9+6.6	NULL
%	NULL
positively	NULL
stained	NULL
cells	NULL
)	NULL
was	NULL
reduced	NULL
by	NULL
66	NULL
%	NULL
(	NULL
18.0+5.3	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CYS	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
and	NULL
67	NULL
%	NULL
(	NULL
17.7+6.9	NULL
%	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
GSH	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
.	NULL

Incubation	NULL
of	NULL
neutrophils	NULL
with	NULL
SMX	NULL
(	NULL
2.5	NULL
mM	NULL
)	NULL
in	NULL
a	NULL
on	NULL
680	NULL
i	NULL
©	NULL
70	NULL
8	NULL
2	NULL
so	NULL
0	NULL
£50	NULL
£40	NULL
8	NULL
so	NULL
.J	NULL
20	NULL
s	NULL
)	NULL
rei	NULL
810	NULL
Co	NULL
A	NULL
1	NULL
10	NULL
Concentration	NULL
(	NULL
uM	NULL
)	NULL
12g	NULL
,	NULL
Control	NULL
2	NULL
C	NULL
©	NULL
>	NULL
LW	NULL
04	NULL
a+	NULL
r	NULL
T	NULL
1	NULL
10	NULL
}	NULL
102	NULL
10°	NULL
104	NULL
FL-2	NULL
x	NULL
Incubation	NULL
with	NULL
:	NULL
®	NULL
SMX	NULL
®	NULL
-	NULL
SMX-NHOH	NULL
A	NULL
SMX-NO	NULL
100	NULL
1000	NULL
128	NULL
,	NULL
SMX-NO	NULL
(	NULL
300uM	NULL
)	NULL
#	NULL
C	NULL
©	NULL
F	NULL
LW	NULL
0	NULL
101	NULL
102	NULL
10°	NULL
104	NULL
FL-2	NULL
Figure	NULL
4	NULL
(	NULL
a	NULL
)	NULL
Neutrophil	NULL
apoptosis	NULL
after	NULL
incubation	NULL
with	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
(	NULL
1-300	NULL
um	NULL
)	NULL
.	NULL

Apoptosis	NULL
was	NULL
measured	NULL
by	NULL
flow	NULL
cytometric	NULL
evaluation	NULL
of	NULL
propidium	NULL
iodide	NULL
stained	NULL
nuclei	NULL
.	NULL

Results	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
experiments	NULL
carried	NULL
out	NULL
in	NULL
triplicate	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
comparing	NULL
the	NULL
ability	NULL
of	NULL
different	NULL
concentrations	NULL
of	NULL
compound	NULL
to	NULL
induce	NULL
apoptosis	NULL
with	NULL
that	NULL
of	NULL
solvent	NULL
alone	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
A	NULL
typical	NULL
trace	NULL
obtained	NULL
from	NULL
the	NULL
flow	NULL
cytometer	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
SMX-NO	NULL
(	NULL
300	NULL
um	NULL
)	NULL
.	NULL

D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
1399	NULL
the	NULL
presence	NULL
of	NULL
PMA	NULL
(	NULL
10	NULL
ng	NULL
ml-	NULL
'	NULL
)	NULL
produced	NULL
significant	NULL
binding	NULL
in	NULL
two	NULL
of	NULL
the	NULL
six	NULL
individuals	NULL
tested	NULL
(	NULL
5	NULL
and	NULL
10	NULL
%	NULL
positively	NULL
stained	NULL
cells	NULL
)	NULL
.	NULL

Cellular	NULL
toxicity	NULL
of	NULL
sulphamethoxazole	NULL
hydroxylamine	NULL
and	NULL
nitroso	NULL
sulphamethoxazole	NULL
The	NULL
toxicity	NULL
of	NULL
the	NULL
oxidative	NULL
metabolites	NULL
of	NULL
SMX	NULL
was	NULL
assessed	NULL
in	NULL
neutrophils	NULL
,	NULL
lymphocytes	NULL
and	NULL
red	NULL
blood	NULL
cells	NULL
.	NULL

In	NULL
neutrophils	NULL
,	NULL
we	NULL
assessed	NULL
both	NULL
functional	NULL
and	NULL
structural	NULL
toxicity	NULL
.	NULL

Both	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
caused	NULL
a	NULL
concentration-dependent	NULL
inhibition	NULL
of	NULL
neutrophil	NULL
function	NULL
as	NULL
assessed	NULL
by	NULL
the	NULL
nitroblue	NULL
tetrazolium	NULL
slide	NULL
test	NULL
and	NULL
inhibition	NULL
of	NULL
eugenol-induced	NULL
GSH	NULL
depletion	NULL
(	NULL
Figure	NULL
3a	NULL
and	NULL
b	NULL
)	NULL
,	NULL
while	NULL
the	NULL
parent	NULL
compound	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

a	NULL
8000	NULL
1	NULL
7000	NULL
+	NULL
E	NULL
soo00+	NULL
s	NULL
5000	NULL
©	NULL
L	NULL
<	NULL
©	NULL
smx	NULL
g	NULL
4099	NULL
1	NULL
BRK	NULL
SMX-NHOH	NULL
g	NULL
'	NULL
3000	NULL
+	NULL
2	NULL
<	NULL
2	NULL
2000	NULL
}	NULL
1000+	NULL
U	NULL
t	NULL
I	NULL
0	NULL
9.2	NULL
1	NULL
8	NULL
20	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
50	NULL
a_	NULL
45	NULL
§	NULL
4	NULL
az	NULL
=	NULL
35	NULL
F=	NULL
&	NULL
30	NULL
2	NULL
as	NULL
A	NULL
SMX-NO	NULL
©	NULL
20	NULL
RK	NULL
SMX-NHOH	NULL
D	NULL
g	NULL
15	NULL
E	NULL
0	NULL
0.5	NULL
1	NULL
8	NULL
24	NULL
48	NULL
72	NULL
96	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
Figure	NULL
5	NULL
Ratio	NULL
of	NULL
product	NULL
formation/disappearance	NULL
in	NULL
the	NULL
reaction	NULL
of	NULL
SMX-NO	NULL
with	NULL
CYS	NULL
(	NULL
a	NULL
)	NULL
under	NULL
aqueous	NULL
conditions	NULL
,	NULL
analysed	NULL
by	NULL
LC-MS	NULL
and	NULL
(	NULL
b	NULL
)	NULL
in	NULL
DMSO	NULL
,	NULL
analysed	NULL
by	NULL
NMR	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
SMX-NO	NULL
could	NULL
not	NULL
be	NULL
measured	NULL
by	NULL
LC-MS	NULL
,	NULL
while	NULL
DMSO	NULL
enhances	NULL
the	NULL
stability	NULL
of	NULL
SMX-NHOH	NULL
(	NULL
see	NULL
text	NULL
)	NULL
.	NULL

Cell	NULL
death	NULL
was	NULL
initially	NULL
assessed	NULL
by	NULL
trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
as	NULL
a	NULL
measure	NULL
of	NULL
membrane	NULL
integrity	NULL
.	NULL

Death	NULL
of	NULL
neutrophils	NULL
after	NULL
a	NULL
1	NULL
h	NULL
incubation	NULL
above	NULL
background	NULL
values	NULL
(	NULL
<	NULL
5	NULL
%	NULL
)	NULL
was	NULL
only	NULL
seen	NULL
with	NULL
1000	NULL
um	NULL
SMX-NO	NULL
(	NULL
7.3	NULL
+1.0	NULL
%	NULL
)	NULL
,	NULL
but	NULL
not	NULL
with	NULL
SMX	NULL
or	NULL
SMX-NHOH	NULL
.	NULL

Lymphocytes	NULL
in	NULL
contrast	NULL
to	NULL
neutrophils	NULL
were	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
more	NULL
sensitive	NULL
to	NULL
the	NULL
direct	NULL
cytotoxic	NULL
effects	NULL
of	NULL
SMX-NO	NULL
(	NULL
1000	NULL
um	NULL
)	NULL
with	NULL
46.8	NULL
+2.8	NULL
%	NULL
cells	NULL
unable	NULL
to	NULL
exclude	NULL
trypan	NULL
blue	NULL
after	NULL
a	NULL
1	NULL
h	NULL
incubation	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
when	NULL
compared	NULL
to	NULL
a	NULL
background	NULL
value	NULL
of	NULL
<	NULL
5	NULL
%	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
the	NULL
mode	NULL
of	NULL
cell	NULL
death	NULL
,	NULL
we	NULL
went	NULL
on	NULL
to	NULL
investigate	NULL
whether	NULL
these	NULL
metabolites	NULL
induced	NULL
apoptosis	NULL
.	NULL

Freshly	NULL
isolated	NULL
neutrophils	NULL
have	NULL
a	NULL
limited	NULL
life	NULL
span	NULL
,	NULL
after	NULL
which	NULL
time	NULL
they	NULL
die	NULL
by	NULL
apoptosis	NULL
.	NULL

The	NULL
background	NULL
rate	NULL
of	NULL
apoptosis	NULL
was	NULL
equivalent	NULL
to	NULL
previous	NULL
studies	NULL
(	NULL
Cox	NULL
,	NULL
1995	NULL
;	NULL
Watson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996a	NULL
)	NULL
.	NULL

Both	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
(	NULL
100-300	NULL
um	NULL
)	NULL
increased	NULL
the	NULL
rate	NULL
of	NULL
spontaneous	NULL
neutrophil	NULL
apoptosis	NULL
as	NULL
assessed	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
Figure	NULL
4a	NULL
)	NULL
and	NULL
morphological	NULL
evaluation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
was	NULL
reduced	NULL
to	NULL
background	NULL
values	NULL
on	NULL
incubation	NULL
with	NULL
GSH	NULL
(	NULL
1	NULL
mm	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

No	NULL
apoptosis	NULL
was	NULL
observed	NULL
with	NULL
SMX	NULL
(	NULL
1-300	NULL
um	NULL
)	NULL
or	NULL
lower	NULL
concentrations	NULL
of	NULL
SMX-NHOH	NULL
(	NULL
1-30	NULL
um	NULL
)	NULL
and	NULL
SMX-NO	NULL
(	NULL
1-30	NULL
um	NULL
)	NULL
.	NULL

Figure	NULL
4b	NULL
illustrates	NULL
a	NULL
typical	NULL
trace	NULL
obtained	NULL
from	NULL
the	NULL
flow	NULL
cytometer	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
SMX-NO	NULL
(	NULL
300	NULL
um	NULL
)	NULL
.	NULL

Lymphocytes	NULL
in	NULL
contrast	NULL
,	NULL
did	NULL
not	NULL
undergo	NULL
apoptosis	NULL
.	NULL

Red	NULL
blood	NULL
cell	NULL
toxicity	NULL
was	NULL
assessed	NULL
by	NULL
measurement	NULL
of	NULL
MetHb	NULL
.	NULL

MetHb	NULL
formation	NULL
with	NULL
SMX-NHOH	NULL
was	NULL
concentra-tion-dependent	NULL
,	NULL
with	NULL
26.1	NULL
+6.4	NULL
%	NULL
(	NULL
control	NULL
,	NULL
1.2	NULL
+	NULL
1.0	NULL
%	NULL
)	NULL
MetHb	NULL
being	NULL
observed	NULL
at	NULL
the	NULL
highest	NULL
concentration	NULL
studied	NULL
(	NULL
100	NULL
um	NULL
SMX-NHOH	NULL
)	NULL
.	NULL

MetHb	NULL
formation	NULL
after	NULL
incubation	NULL
of	NULL
red	NULL
blood	NULL
cells	NULL
with	NULL
SMX-NO	NULL
(	NULL
30	NULL
um	NULL
;	NULL
4.9+0.8	NULL
%	NULL
)	NULL
was	NULL
lower	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
than	NULL
that	NULL
observed	NULL
with	NULL
an	NULL
equimolar	NULL
concentration	NULL
of	NULL
SMX-NHOH	NULL
(	NULL
10.2+3.1	NULL
%	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
nitroso	NULL
sulphamethoxazole	NULL
on	NULL
redox	NULL
sensitive	NULL
transcription	NULL
factors	NULL
NF-xB	NULL
and	NULL
AP-1	NULL
in	NULL
mononuclear	NULL
leukocytes	NULL
SMX-NO	NULL
(	NULL
1000	NULL
um	NULL
)	NULL
caused	NULL
a	NULL
decrease	NULL
in	NULL
basal	NULL
levels	NULL
of	NULL
NF-kB	NULL
in	NULL
lymphocytes	NULL
after	NULL
1h	NULL
(	NULL
control	NULL
,	NULL
1779+213	NULL
arbitrary	NULL
units	NULL
;	NULL
drug	NULL
treated	NULL
,	NULL
968	NULL
+359	NULL
arbitrary	NULL
units	NULL
;	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
incubation	NULL
of	NULL
SMX-NO	NULL
(	NULL
1000	NULL
um	NULL
)	NULL
with	NULL
these	NULL
cells	NULL
produced	NULL
a	NULL
strong	NULL
induction	NULL
of	NULL
AP-1	NULL
(	NULL
control	NULL
,	NULL
242+193	NULL
arbitrary	NULL
units	NULL
;	NULL
drug	NULL
treated	NULL
,	NULL
1157	NULL
+196	NULL
arbitrary	NULL
units	NULL
;	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

Neither	NULL
NF-xB	NULL
nor	NULL
AP-1	NULL
levels	NULL
were	NULL
altered	NULL
at	NULL
lower	NULL
SMX-NO	NULL
concentrations	NULL
(	NULL
1100	NULL
um	NULL
)	NULL
.	NULL

Reaction	NULL
of	NULL
sulphamethoxazole	NULL
,	NULL
sulphamethoxazole	NULL
hydroxylamine	NULL
and	NULL
nitroso	NULL
sulphamethoxazole	NULL
with	NULL
thiols	NULL
Figure	NULL
5a	NULL
and	NULL
b	NULL
show	NULL
the	NULL
reaction	NULL
of	NULL
SMX-NO	NULL
with	NULL
CYS	NULL
analysed	NULL
by	NULL
LC-MS	NULL
and	NULL
NMR	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
initial	NULL
product	NULL
was	NULL
SMX-NHOH	NULL
;	NULL
this	NULL
largely	NULL
(	NULL
95	NULL
%	NULL
)	NULL
underwent	NULL
further	NULL
reduction	NULL
to	NULL
SMX	NULL
during	NULL
the	NULL
first	NULL
8	NULL
h	NULL
of	NULL
the	NULL
incubation	NULL
.	NULL

Semi-mercaptal	NULL
and	NULL
sulphonamide	NULL
conjugates	NULL
which	NULL
are	NULL
formed	NULL
when	NULL
SMX-NO	NULL
reacts	NULL
with	NULL
GSH	NULL
and	NULL
other	NULL
biological	NULL
thiols	NULL
(	NULL
Cribb	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Naisbitt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
were	NULL
not	NULL
detected	NULL
.	NULL

SMX	NULL
was	NULL
the	NULL
only	NULL
product	NULL
when	NULL
SMX-NHOH	NULL
and	NULL
CYS	NULL
were	NULL
incubated	NULL
in	NULL
buffer	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
(	NULL
1-300	NULL
um	NULL
)	NULL
both	NULL
caused	NULL
concentration-dependent	NULL
depletion	NULL
of	NULL
CYS	NULL
(	NULL
3	NULL
um	NULL
)	NULL
and	NULL
GSH	NULL
1400	NULL
D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
(	NULL
3	NULL
um	NULL
)	NULL
(	NULL
Figure	NULL
Ga	NULL
and	NULL
b	NULL
)	NULL
,	NULL
while	NULL
SMX	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

The	NULL
reaction	NULL
between	NULL
SMX-NO	NULL
(	NULL
30	NULL
um	NULL
)	NULL
and	NULL
CYS	NULL
(	NULL
10	NULL
um	NULL
)	NULL
was	NULL
rapid	NULL
resulting	NULL
in	NULL
92.4+3.2	NULL
%	NULL
depletion	NULL
within	NULL
1	NULL
min	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
reaction	NULL
with	NULL
GSH	NULL
was	NULL
significantly	NULL
slower	NULL
than	NULL
with	NULL
CYS	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
,	NULL
with	NULL
63.6+5.4	NULL
%	NULL
depletion	NULL
being	NULL
observed	NULL
after	NULL
1	NULL
min	NULL
.	NULL

CYS	NULL
was	NULL
completely	NULL
depleted	NULL
after	NULL
10	NULL
min	NULL
,	NULL
while	NULL
a	NULL
significant	NULL
amount	NULL
of	NULL
GSH	NULL
remained	NULL
for	NULL
a	NULL
further	NULL
20	NULL
min	NULL
.	NULL

Thiol	NULL
depletion	NULL
from	NULL
human	NULL
neutrophils	NULL
,	NULL
lymphocytes	NULL
and	NULL
plasma	NULL
by	NULL
sulphamethoxazole	NULL
and	NULL
its	NULL
metabolites	NULL
The	NULL
basal	NULL
intracellular	NULL
GSH	NULL
concentration	NULL
measured	NULL
in	NULL
20	NULL
individuals	NULL
(	NULL
3.2-5.6	NULL
nmoles/10®	NULL
cells	NULL
)	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
reported	NULL
previously	NULL
(	NULL
Cotgreave	NULL
&	NULL
Moldeus	NULL
,	NULL
1986	NULL
;	NULL
Pirmohamed	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

CYS	NULL
was	NULL
present	NULL
almost	NULL
exclusively	NULL
in	NULL
a	NULL
Cysteine	NULL
(	NULL
%	NULL
)	NULL
\	NULL
--	NULL
t	NULL
0	NULL
1	NULL
10	NULL
Concentration	NULL
(	NULL
uM	NULL
)	NULL
Glutathione	NULL
(	NULL
%	NULL
)	NULL
NJ	NULL
O	NULL
plasma	NULL
,	NULL
with	NULL
control	NULL
values	NULL
(	NULL
7.1-15.0	NULL
uM	NULL
,	NULL
measured	NULL
in	NULL
ten	NULL
individuals	NULL
)	NULL
again	NULL
being	NULL
similar	NULL
to	NULL
those	NULL
reported	NULL
previously	NULL
(	NULL
Mills	NULL
&	NULL
Lang	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

In	NULL
control	NULL
incubations	NULL
,	NULL
there	NULL
was	NULL
no	NULL
significant	NULL
decrease	NULL
in	NULL
either	NULL
the	NULL
CYS	NULL
or	NULL
GSH	NULL
levels	NULL
for	NULL
the	NULL
duration	NULL
of	NULL
the	NULL
experiment	NULL
(	NULL
1	NULL
h	NULL
)	NULL
,	NULL
although	NULL
2.5	NULL
h	NULL
after	NULL
cell	NULL
isolation	NULL
,	NULL
CYS	NULL
levels	NULL
were	NULL
reduced	NULL
by	NULL
24-37	NULL
%	NULL
.	NULL

Neither	NULL
SMX-NHOH	NULL
nor	NULL
SMX-NO	NULL
(	NULL
up	NULL
to	NULL
400	NULL
uM	NULL
)	NULL
depleted	NULL
GSH	NULL
in	NULL
PMA-stimulated	NULL
and	NULL
unstimulated	NULL
neutrophils	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
GSH	NULL
depletion	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
was	NULL
observed	NULL
in	NULL
lymphocytes	NULL
with	NULL
both	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
at	NULL
concentrations	NULL
of	NULL
10	NULL
uM	NULL
or	NULL
greater	NULL
.	NULL

GSH	NULL
depletion	NULL
was	NULL
significantly	NULL
greater	NULL
when	NULL
neutrophils	NULL
were	NULL
lysed	NULL
than	NULL
when	NULL
they	NULL
were	NULL
intact	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
;	NULL
the	NULL
concentration	NULL
of	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
which	NULL
caused	NULL
50	NULL
%	NULL
depletion	NULL
in	NULL
lysed	NULL
cells	NULL
was	NULL
11.1	NULL
+1.4	NULL
um	NULL
and	NULL
2.9+0.6	NULL
uM	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
greater	NULL
than	NULL
90	NULL
%	NULL
depletion	NULL
was	NULL
observed	NULL
at	NULL
30	NULL
uM	NULL
(	NULL
Figure	NULL
7a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

Reaction	NULL
of	NULL
cysteine	NULL
NH	NULL
HSWOH	NULL
O	NULL
with	NULL
:	NULL
©	NULL
SMX	NULL
®	NULL
SMX-NHOH	NULL
A	NULL
SMX-NO	NULL
Reaction	NULL
of	NULL
glutathione	NULL
0	NULL
O.	NULL
OH	NULL
HSWNHJkOH	NULL
with	NULL
:	NULL
_	NULL
0	NULL
©	NULL
SMX	NULL
®	NULL
SMX-NHOH	NULL
A	NULL
SMX-NO	NULL
\-	NULL
U	NULL
0	NULL
1	NULL
10	NULL
Concentration	NULL
(	NULL
uM	NULL
)	NULL
1	NULL
100	NULL
Figure	NULL
6	NULL
Reaction	NULL
of	NULL
CYS	NULL
(	NULL
a	NULL
)	NULL
or	NULL
GSH	NULL
(	NULL
b	NULL
)	NULL
with	NULL
SMX	NULL
and	NULL
its	NULL
metabolites	NULL
.	NULL

Unreacted	NULL
sulphydryl	NULL
concentrations	NULL
,	NULL
expressed	NULL
as	NULL
percentage	NULL
of	NULL
thiol	NULL
depletion	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
drug	NULL
,	NULL
were	NULL
measured	NULL
by	NULL
fluorimetric	NULL
HPLC	NULL
following	NULL
conjugation	NULL
with	NULL
bromobimane	NULL
,	NULL
after	NULL
incubation	NULL
of	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
or	NULL
SMX-NO	NULL
(	NULL
1-100	NULL
um	NULL
)	NULL
for	NULL
1	NULL
h	NULL
with	NULL
either	NULL
CYS	NULL
(	NULL
3	NULL
um	NULL
)	NULL
or	NULL
GSH	NULL
(	NULL
3	NULL
um	NULL
)	NULL
.	NULL

The	NULL
results	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
experiments	NULL
conducted	NULL
in	NULL
triplicate	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
comparing	NULL
the	NULL
depletion	NULL
of	NULL
thiols	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
SMX	NULL
or	NULL
its	NULL
metabolites	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
1401	NULL
Both	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
caused	NULL
a	NULL
concentration-dependent	NULL
depletion	NULL
of	NULL
CYS	NULL
in	NULL
plasma	NULL
.	NULL

At	NULL
the	NULL
highest	NULL
concentration	NULL
(	NULL
400	NULL
uM	NULL
)	NULL
tested	NULL
,	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
caused	NULL
82.3	NULL
+4.7	NULL
and	NULL
90.3	NULL
+	NULL
3.1	NULL
%	NULL
depletion	NULL
,	NULL
respectively	NULL
,	NULL
when	NULL
compared	NULL
with	NULL
the	NULL
control	NULL
values	NULL
(	NULL
Figure	NULL
7¢	NULL
)	NULL
.	NULL

SMX	NULL
itself	NULL
did	NULL
not	NULL
deplete	NULL
either	NULL
GSH	NULL
or	NULL
CYS	NULL
in	NULL
plasma	NULL
,	NULL
intact	NULL
or	NULL
lysed	NULL
cells	NULL
.	NULL

a	NULL
Neutrophils	NULL
120	NULL
;	NULL
-	NULL
>	NULL
&	NULL
&	NULL
co	NULL
O	NULL
[	NULL
Z	NULL
]	NULL
Lysed	NULL
cells	NULL
WW	NULL
Intact	NULL
cells	NULL
Glutathione	NULL
(	NULL
%	NULL
)	NULL
3	NULL
-	NULL
S3	NULL
ho	NULL
O	NULL
1	NULL
10	NULL
100	NULL
Concentration	NULL
(	NULL
uM	NULL
)	NULL
c	NULL
Plasma	NULL
120	NULL
¢	NULL
;	NULL
Cysteine	NULL
(	NULL
%	NULL
)	NULL
8	NULL
-	NULL
8	NULL
S8	NULL
s	NULL
ho	NULL
O	NULL
0	NULL
A	NULL
--	NULL
+	NULL
+	NULL
50g	NULL
10	NULL
100	NULL
Concentration	NULL
(	NULL
uM	NULL
)	NULL
1000	NULL
Reduction	NULL
of	NULL
sulphamethoxazole	NULL
hydroxylamine	NULL
and	NULL
nitroso	NULL
sulphamethoxazole	NULL
by	NULL
the	NULL
individual	NULL
components	NULL
of	NULL
peripheral	NULL
blood	NULL
There	NULL
was	NULL
no	NULL
spontaneous	NULL
reduction	NULL
of	NULL
SMX-NHOH	NULL
or	NULL
SMX-NO	NULL
after	NULL
a	NULL
1	NULL
h	NULL
incubation	NULL
in	NULL
either	NULL
buffer	NULL
,	NULL
mobile	NULL
phase	NULL
b	NULL
Lymphocytes	NULL
120	NULL
;	NULL
_s	NULL
O	NULL
=J	NULL
C	NULL
O	NULL
J	NULL
O	NULL
Glutathione	NULL
(	NULL
%	NULL
)	NULL
&	NULL
20	NULL
0	NULL
\-	NULL
A	NULL
e	NULL
1	NULL
10	NULL
100	NULL
Concentration	NULL
(	NULL
uM	NULL
)	NULL
1000	NULL
Incubation	NULL
with	NULL
:	NULL
©	NULL
SMX	NULL
im	NULL
SMX-NHOH	NULL
A	NULL
SMX-NO	NULL
Figure	NULL
7	NULL
Depletion	NULL
of	NULL
CYS	NULL
and	NULL
GSH	NULL
from	NULL
cells	NULL
and	NULL
plasma	NULL
after	NULL
incubation	NULL
with	NULL
SMX	NULL
and	NULL
its	NULL
metabolites	NULL
.	NULL

Thiol	NULL
levels	NULL
in	NULL
neutrophils	NULL
,	NULL
lysed	NULL
neutrophils	NULL
(	NULL
0.5	NULL
x	NULL
10°	NULL
;	NULL
a	NULL
)	NULL
,	NULL
lymphocytes	NULL
(	NULL
0.5	NULL
x	NULL
10°	NULL
;	NULL
b	NULL
)	NULL
,	NULL
and	NULL
plasma	NULL
(	NULL
1	NULL
ml	NULL
;	NULL
c	NULL
)	NULL
were	NULL
measured	NULL
with	NULL
fluorescent	NULL
HPLC	NULL
detection	NULL
using	NULL
bromobimane	NULL
after	NULL
incubation	NULL
with	NULL
either	NULL
SMX	NULL
,	NULL
SMX-NHOH	NULL
or	NULL
SMX-NO	NULL
(	NULL
1-400	NULL
um	NULL
)	NULL
.	NULL

Results	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
experiments	NULL
carried	NULL
out	NULL
in	NULL
triplicate	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
comparing	NULL
depletion	NULL
at	NULL
different	NULL
concentrations	NULL
of	NULL
drug	NULL
with	NULL
that	NULL
in	NULL
solvent	NULL
alone	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

Error	NULL
bars	NULL
have	NULL
been	NULL
omitted	NULL
for	NULL
clarity	NULL
when	NULL
there	NULL
was	NULL
no	NULL
significant	NULL
depletion	NULL
.	NULL

1402	NULL
D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
Table	NULL
1	NULL
Reduction	NULL
of	NULL
30	NULL
um	NULL
SMX-NHOH	NULL
or	NULL
SMX-NO	NULL
by	NULL
human	NULL
neutrophils	NULL
,	NULL
lymphocytes	NULL
,	NULL
red	NULL
blood	NULL
cells	NULL
and	NULL
plasma	NULL
after	NULL
1h	NULL
Neutrophils	NULL
+	NULL
PMA	NULL
3.0+0.8	NULL
Neutrophils-PMA	NULL
2.6+0.2	NULL
Lysed	NULL
neutrophils	NULL
2.5+0.4	NULL
Lymphocytes	NULL
2.9+1.1	NULL
Lysed	NULL
lymphocytes	NULL
24+0.3	NULL
Red	NULL
blood	NULL
cells	NULL
12.1	NULL
+24	NULL
Plasma	NULL
4.8	NULL
+1.1	NULL
Control	NULL
values	NULL
(	NULL
<	NULL
1	NULL
%	NULL
)	NULL
are	NULL
subtracted	NULL
from	NULL
the	NULL
tabulated	NULL
values	NULL
.	NULL

or	NULL
solvent	NULL
.	NULL

All	NULL
components	NULL
of	NULL
peripheral	NULL
blood	NULL
were	NULL
able	NULL
to	NULL
reduce	NULL
SMX-NHOH	NULL
to	NULL
SMX	NULL
,	NULL
and	NULL
SMX-NO	NULL
to	NULL
the	NULL
SMX-NHOH	NULL
and	NULL
SMX	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Intact	NULL
neutrophils	NULL
,	NULL
lymphocytes	NULL
and	NULL
plasma	NULL
were	NULL
equipotent	NULL
at	NULL
reducing	NULL
the	NULL
nitroso	NULL
metabolite	NULL
back	NULL
to	NULL
the	NULL
hydroxylamine	NULL
,	NULL
while	NULL
red	NULL
blood	NULL
cells	NULL
were	NULL
most	NULL
potent	NULL
at	NULL
reducing	NULL
SMX-NHOH	NULL
back	NULL
to	NULL
SMX	NULL
.	NULL

Lysis	NULL
of	NULL
neutrophils	NULL
decreased	NULL
the	NULL
capacity	NULL
for	NULL
reduction	NULL
of	NULL
SMX-NO	NULL
to	NULL
SMX-NHOH	NULL
by	NULL
12-16	NULL
fold	NULL
.	NULL

SMX	NULL
is	NULL
converted	NULL
to	NULL
the	NULL
electrophilic	NULL
hydroxylamine	NULL
metabolite	NULL
in	NULL
neutrophils	NULL
(	NULL
Cribb	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
reaction	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
catalyzed	NULL
by	NULL
myeloperoxidase	NULL
.	NULL

In	NULL
vitro	NULL
activation	NULL
of	NULL
myeloperoxidase	NULL
requires	NULL
an	NULL
artificial	NULL
stimuli	NULL
such	NULL
as	NULL
phorbol	NULL
esters	NULL
or	NULL
fMLP	NULL
.	NULL

In	NULL
this	NULL
study	NULL
PMA	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
cells	NULL
capacity	NULL
for	NULL
reduction	NULL
.	NULL

The	NULL
reduction	NULL
of	NULL
SMX-NO	NULL
to	NULL
SMX-NHOH	NULL
was	NULL
dependent	NULL
on	NULL
cell	NULL
concentration	NULL
,	NULL
with	NULL
less	NULL
than	NULL
20	NULL
%	NULL
reduction	NULL
being	NULL
observed	NULL
at	NULL
0.5	NULL
x	NULL
10°	NULL
neutrophils/ml	NULL
(	NULL
Figure	NULL
8a	NULL
)	NULL
.	NULL

Salicyl	NULL
hydroxamate	NULL
,	NULL
dicoumarol	NULL
and	NULL
sodium	NULL
azide	NULL
caused	NULL
a	NULL
significant	NULL
decrease	NULL
in	NULL
the	NULL
reduction	NULL
of	NULL
SMX-NO	NULL
to	NULL
SMX-NHOH	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
,	NULL
while	NULL
neocuprin	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Figure	NULL
8b	NULL
)	NULL
.	NULL

The	NULL
inhibitors	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
SMX	NULL
formation	NULL
.	NULL

Accumulation	NULL
of	NULL
sulphamethoxazole	NULL
hydroxylamine	NULL
and	NULL
dapsone	NULL
hydroxylamine	NULL
into	NULL
red	NULL
blood	NULL
cells	NULL
Dapsone	NULL
hydroxylamine	NULL
was	NULL
taken	NULL
up	NULL
rapidly	NULL
into	NULL
the	NULL
red	NULL
blood	NULL
cells	NULL
,	NULL
with	NULL
92.9+0.8	NULL
%	NULL
partitioning	NULL
into	NULL
the	NULL
cells	NULL
over	NULL
90	NULL
min	NULL
.	NULL

In	NULL
comparison	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
SMX-NHOH	NULL
taken	NULL
up	NULL
into	NULL
red	NULL
cells	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
lower	NULL
(	NULL
33.1+13.1	NULL
%	NULL
;	NULL
Figure	NULL
9	NULL
)	NULL
.	NULL

Discussion	NULL
The	NULL
demonstration	NULL
of	NULL
cell-mediated	NULL
immunity	NULL
(	NULL
Mauri-Hellweg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
and	NULL
anti-SMX	NULL
antibodies	NULL
(	NULL
Daftarian	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
in	NULL
hypersensitive	NULL
patients	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
SMX-substituted	NULL
proteins	NULL
in	NULL
patient	NULL
sera	NULL
(	NULL
Meekins	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
are	NULL
indicative	NULL
of	NULL
an	NULL
immune	NULL
pathogenesis	NULL
for	NULL
the	NULL
toxicity	NULL
associated	NULL
with	NULL
the	NULL
drug	NULL
.	NULL

Bioactivation	NULL
of	NULL
SMX	NULL
to	NULL
the	NULL
hydroxylamine	NULL
and	NULL
thence	NULL
to	NULL
the	NULL
nitroso	NULL
metabolite	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
the	NULL
initial	NULL
step	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
hypersensitivity	NULL
reactions	NULL
(	NULL
Rieder	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995a	NULL
,	NULL
b	NULL
;	NULL
1988	NULL
;	NULL
Carr	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
with	NULL
subsequent	NULL
formation	NULL
of	NULL
drug-associated	NULL
antigen	NULL
by	NULL
drug-protein	NULL
conjugation	NULL
.	NULL

Alternatively	NULL
it	NULL
has	NULL
been	NULL
postulated	NULL
that	NULL
the	NULL
drug	NULL
,	NULL
or	NULL
drug	NULL
metabolite	NULL
,	NULL
exerts	NULL
a	NULL
direct	NULL
immunotoxic	NULL
effect	NULL
on	NULL
cells	NULL
to	NULL
produce	NULL
a	NULL
hypersensitivity	NULL
reaction	NULL
(	NULL
Schnyder	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

We	NULL
have	NULL
therefore	NULL
explored	NULL
the	NULL
relationship	NULL
between	NULL
drug-antigen	NULL
formation	NULL
,	NULL
drug	NULL
(	NULL
metabolite	NULL
)	NULL
disposition	NULL
,	NULL
and	NULL
cell-function	NULL
,	NULL
by	NULL
use	NULL
of	NULL
%	NULL
Reduction	NULL
N=O~-NH	NULL
N=O0-NHOH	NULL
1.8+0.6	NULL
35.3+3.6	NULL
1.7+0.4	NULL
41.0	NULL
+7.2	NULL
7.8+0.6	NULL
3.2+2.6	NULL
2.8	NULL
+0.5	NULL
49.3	NULL
+	NULL
5.4	NULL
7.9+0.3	NULL
3.1	NULL
+0.3	NULL
6.2+1.3	NULL
17.2+3.6	NULL
16.3+3.6	NULL
45.0	NULL
+	NULL
10.3	NULL
g	NULL
)	NULL
SMX-NHOH	NULL
formation	NULL
(	NULL
%	NULL
)	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
Neutrophil	NULL
number	NULL
(	NULL
x108/ml	NULL
)	NULL
T	NULL
SMX-NHOH	NULL
formation	NULL
(	NULL
%	NULL
)	NULL
Figure	NULL
8	NULL
(	NULL
a	NULL
)	NULL
Reduction	NULL
of	NULL
SMX-NO	NULL
to	NULL
SMX-NHOH	NULL
by	NULL
neutrophils	NULL
(	NULL
0.005-5	NULL
x	NULL
10°	NULL
ml-	NULL
'	NULL
)	NULL
in	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Inhibition	NULL
of	NULL
neutrophil	NULL
(	NULL
5x	NULL
10°	NULL
ml~	NULL
'	NULL
)	NULL
mediated	NULL
reduction	NULL
of	NULL
SMX-NO	NULL
(	NULL
30	NULL
um	NULL
)	NULL
after	NULL
co-incubation	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
neocuproin	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
,	NULL
sodium	NULL
azide	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
,	NULL
dicoumarol	NULL
(	NULL
10	NULL
um	NULL
)	NULL
or	NULL
salicyl	NULL
hydroxamate	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
.	NULL

SMX-NHOH	NULL
formation	NULL
was	NULL
measured	NULL
by	NULL
HPLC	NULL
with	NULL
UV	NULL
detection	NULL
.	NULL

Results	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
experiments	NULL
carried	NULL
out	NULL
in	NULL
duplicate	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
comparing	NULL
SMX-NHOH	NULL
formation	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
the	NULL
inhibitors	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
1403	NULL
Accumulation	NULL
(	NULL
%	NULL
)	NULL
Time	NULL
(	NULL
min	NULL
)	NULL
Incubation	NULL
with	NULL
:	NULL
©	NULL
SMX-NHOH	NULL
O	NULL
Dapsone	NULL
NHOH	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
70	NULL
80	NULL
90	NULL
Figure	NULL
9	NULL
Time-dependent	NULL
accumulation	NULL
of	NULL
dapsone	NULL
hydroxylamine	NULL
(	NULL
10	NULL
um	NULL
)	NULL
and	NULL
SMX-NHOH	NULL
(	NULL
10	NULL
um	NULL
)	NULL
by	NULL
red	NULL
blood	NULL
cells	NULL
.	NULL

The	NULL
hydroxylamines	NULL
were	NULL
measured	NULL
by	NULL
HPLC	NULL
with	NULL
UV	NULL
and	NULL
electrochemical	NULL
detection	NULL
.	NULL

Results	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
four	NULL
experiments	NULL
carried	NULL
out	NULL
in	NULL
triplicate	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
comparing	NULL
the	NULL
difference	NULL
in	NULL
the	NULL
cellular	NULL
uptake	NULL
of	NULL
dapsone	NULL
hydroxylamine	NULL
and	NULL
SMX-NHOH	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

two	NULL
accessible	NULL
human	NULL
cell	NULL
types	NULL
,	NULL
neutrophils	NULL
and	NULL
lymphocytes	NULL
.	NULL

Use	NULL
of	NULL
flow	NULL
cytometry	NULL
,	NULL
in	NULL
conjunction	NULL
with	NULL
a	NULL
specific	NULL
anti-SMX	NULL
antibody	NULL
,	NULL
clearly	NULL
demonstrated	NULL
the	NULL
ability	NULL
of	NULL
both	NULL
SMX-NHOH	NULL
and	NULL
SMX-NO	NULL
,	NULL
but	NULL
not	NULL
SMX	NULL
itself	NULL
,	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
outer	NULL
surface	NULL
of	NULL
neutrophils	NULL
and	NULL
lymphocytes	NULL
in	NULL
a	NULL
concentration-dependent	NULL
fashion	NULL
.	NULL

Haptenation	NULL
was	NULL
greater	NULL
with	NULL
SMX-NO	NULL
.	NULL

Binding	NULL
of	NULL
SMX-NHOH	NULL
is	NULL
presumed	NULL
to	NULL
involve	NULL
autoxidation	NULL
to	NULL
SMX-NO	NULL
(	NULL
Cribb	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
which	NULL
can	NULL
react	NULL
with	NULL
CYS	NULL
but	NULL
not	NULL
with	NULL
other	NULL
amino	NULL
acids	NULL
(	NULL
Naisbitt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
there	NULL
was	NULL
detectable	NULL
binding	NULL
to	NULL
albumin	NULL
only	NULL
when	NULL
the	NULL
protein	NULL
was	NULL
chemically	NULL
modified	NULL
to	NULL
increase	NULL
its	NULL
free	NULL
thiol	NULL
content	NULL
.	NULL

Furthermore	NULL
,	NULL
an	NULL
increase	NULL
in	NULL
extracellular	NULL
GSH	NULL
(	NULL
or	NULL
CYS	NULL
)	NULL
blocked	NULL
cell-haptenation	NULL
by	NULL
SMX-NO	NULL
.	NULL

Cell-surface	NULL
haptenation	NULL
was	NULL
detectable	NULL
after	NULL
exposure	NULL
to	NULL
drug	NULL
metabolite	NULL
concentrations	NULL
of	NULL
10	NULL
um	NULL
which	NULL
may	NULL
occur	NULL
after	NULL
a	NULL
therapeutic	NULL
dose	NULL
of	NULL
SMX	NULL
(	NULL
Mitra	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
in	NULL
accordance	NULL
with	NULL
the	NULL
finding	NULL
that	NULL
there	NULL
are	NULL
high	NULL
levels	NULL
of	NULL
protein	NULL
thiols	NULL
expressed	NULL
extracellularly	NULL
in	NULL
cells	NULL
such	NULL
as	NULL
lymphocytes	NULL
(	NULL
Lawrence	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
haptenation	NULL
can	NULL
occur	NULL
without	NULL
loss	NULL
of	NULL
cell	NULL
membrane	NULL
integrity	NULL
,	NULL
depletion	NULL
of	NULL
intracellular	NULL
GSH	NULL
or	NULL
detectable	NULL
perturbation	NULL
of	NULL
redox	NULL
sensitive	NULL
transcription	NULL
factors	NULL
.	NULL

The	NULL
evidence	NULL
for	NULL
this	NULL
is	NULL
3	NULL
fold	NULL
.	NULL

First	NULL
,	NULL
the	NULL
system	NULL
used	NULL
to	NULL
detect	NULL
cell-surface	NULL
haptenation	NULL
will	NULL
distinguish	NULL
between	NULL
viable	NULL
and	NULL
non-viable	NULL
cells	NULL
,	NULL
and	NULL
haptenation	NULL
was	NULL
clearly	NULL
occurring	NULL
on	NULL
viable	NULL
cells	NULL
.	NULL

Second	NULL
,	NULL
although	NULL
SMX-NO	NULL
and	NULL
SMX-NHOH	NULL
are	NULL
toxic	NULL
to	NULL
lymphocytes	NULL
,	NULL
loss	NULL
of	NULL
membrane	NULL
integrity	NULL
was	NULL
only	NULL
observed	NULL
at	NULL
concentrations	NULL
of	NULL
100	NULL
uM	NULL
and	NULL
greater	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
concentrations	NULL
of	NULL
SMX-NO	NULL
required	NULL
to	NULL
induce	NULL
apoptosis	NULL
(	NULL
100-300	NULL
um	NULL
)	NULL
and	NULL
necrosis	NULL
(	NULL
1000	NULL
uM	NULL
)	NULL
in	NULL
neutrophils	NULL
,	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
outside	NULL
the	NULL
range	NULL
achieved	NULL
with	NULL
therapeutic	NULL
doses	NULL
of	NULL
SMX	NULL
.	NULL

Lymphocytes	NULL
were	NULL
more	NULL
sensitive	NULL
to	NULL
the	NULL
direct	NULL
cytotoxic	NULL
effects	NULL
of	NULL
SMX-NO	NULL
,	NULL
but	NULL
did	NULL
not	NULL
undergo	NULL
apoptosis	NULL
.	NULL

The	NULL
differential	NULL
extent	NULL
of	NULL
toxicity	NULL
in	NULL
neutrophils	NULL
and	NULL
lymphocytes	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
significant	NULL
GSH	NULL
depletion	NULL
observed	NULL
with	NULL
high	NULL
concentrations	NULL
of	NULL
SMX-NO	NULL
in	NULL
lymphocytes	NULL
.	NULL

SMX	NULL
itself	NULL
was	NULL
non-toxic	NULL
to	NULL
either	NULL
cell	NULL
type	NULL
.	NULL

Third	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
effect	NULL
on	NULL
the	NULL
redox	NULL
sensitive	NULL
transcription	NULL
factors	NULL
,	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
,	NULL
known	NULL
to	NULL
be	NULL
modified	NULL
under	NULL
situations	NULL
of	NULL
cellular	NULL
stress	NULL
and	NULL
initiation	NULL
of	NULL
an	NULL
immune	NULL
response	NULL
(	NULL
Angel	NULL
&	NULL
Karin	NULL
,	NULL
1991	NULL
;	NULL
Bacuerle	NULL
&	NULL
Henkel	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

Although	NULL
SMX-NO	NULL
did	NULL
cause	NULL
changes	NULL
in	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
probes	NULL
,	NULL
consistent	NULL
with	NULL
altered	NULL
protein	NULL
binding	NULL
,	NULL
these	NULL
changes	NULL
only	NULL
occurred	NULL
at	NULL
concentrations	NULL
above	NULL
those	NULL
seen	NULL
therapeutically	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
1000	NULL
um	NULL
)	NULL
and	NULL
appeared	NULL
to	NULL
coincide	NULL
with	NULL
perturbation	NULL
of	NULL
membrane	NULL
integrity	NULL
.	NULL

Similar	NULL
results	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
the	NULL
liver	NULL
,	NULL
after	NULL
administration	NULL
of	NULL
hepatotoxic	NULL
doses	NULL
of	NULL
paracetamol	NULL
to	NULL
mice	NULL
(	NULL
Blazka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
1997	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
show	NULL
that	NULL
SMX-NO	NULL
can	NULL
haptenate	NULL
cells	NULL
without	NULL
loss	NULL
of	NULL
viability	NULL
.	NULL

Such	NULL
viable	NULL
cell-drug	NULL
conjugates	NULL
can	NULL
function	NULL
as	NULL
a	NULL
potent	NULL
antigenic	NULL
stimulus	NULL
in	NULL
vivo	NULL
.	NULL

For	NULL
example	NULL
,	NULL
dinitrophenyl	NULL
conjugated	NULL
to	NULL
lymphocytes	NULL
at	NULL
extremely	NULL
low	NULL
hapten	NULL
densities	NULL
was	NULL
shown	NULL
to	NULL
elicit	NULL
hypersensitivity	NULL
reactions	NULL
to	NULL
a	NULL
significantly	NULL
greater	NULL
extent	NULL
than	NULL
similar	NULL
amounts	NULL
of	NULL
dinitrophenyl	NULL
conjugated	NULL
to	NULL
serum	NULL
proteins	NULL
(	NULL
Sjoeberg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1978	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
lymphocytes	NULL
pre-treated	NULL
with	NULL
the	NULL
reactive	NULL
metabolite	NULL
of	NULL
halothane	NULL
,	NULL
were	NULL
found	NULL
to	NULL
be	NULL
highly	NULL
immunogenic	NULL
when	NULL
administered	NULL
to	NULL
rabbits	NULL
(	NULL
Hastings	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Conjugation	NULL
of	NULL
external	NULL
cellular	NULL
proteins	NULL
may	NULL
lead	NULL
to	NULL
internalization	NULL
,	NULL
antigen	NULL
processing	NULL
and	NULL
,	NULL
ultimately	NULL
,	NULL
to	NULL
presentation	NULL
of	NULL
drug-peptide	NULL
conjugates	NULL
which	NULL
are	NULL
then	NULL
recognized	NULL
by	NULL
specific	NULL
CD8	NULL
*	NULL
T-cells	NULL
(	NULL
Park	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
,	NULL
thus	NULL
providing	NULL
a	NULL
mechanism	NULL
for	NULL
drug	NULL
hypersensitivity	NULL
reactions	NULL
.	NULL

Haptenation	NULL
of	NULL
viable	NULL
cells	NULL
is	NULL
essential	NULL
for	NULL
each	NULL
of	NULL
these	NULL
processes	NULL
to	NULL
function	NULL
unimpaired	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
SMX	NULL
,	NULL
and	NULL
its	NULL
oxidative	NULL
metabolites	NULL
to	NULL
interact	NULL
selectively	NULL
with	NULL
target	NULL
cells	NULL
,	NULL
will	NULL
be	NULL
partly	NULL
dependent	NULL
on	NULL
the	NULL
balance	NULL
between	NULL
various	NULL
pathways	NULL
of	NULL
drug	NULL
metabolism	NULL
.	NULL

In	NULL
the	NULL
liver	NULL
,	NULL
acetylation	NULL
and	NULL
glucuronidation	NULL
represent	NULL
direct	NULL
detoxification	NULL
processes	NULL
whereas	NULL
N-hydroxylation	NULL
represents	NULL
bioac-tivation	NULL
.	NULL

Accordingly	NULL
,	NULL
relative	NULL
dysfunction	NULL
of	NULL
either	NULL
of	NULL
these	NULL
phase	NULL
II	NULL
biotransformations	NULL
may	NULL
predispose	NULL
to	NULL
drug	NULL
toxicity	NULL
(	NULL
Shear	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
liver	NULL
is	NULL
the	NULL
major	NULL
site	NULL
of	NULL
hydroxylamine	NULL
formation	NULL
,	NULL
hepatotoxicity	NULL
is	NULL
only	NULL
rarely	NULL
associated	NULL
with	NULL
SMX	NULL
(	NULL
Cribb	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996a	NULL
)	NULL
.	NULL

GSH	NULL
and	NULL
the	NULL
GSH	NULL
transferase	NULL
enzymes	NULL
are	NULL
known	NULL
to	NULL
be	NULL
important	NULL
in	NULL
the	NULL
prevention	NULL
of	NULL
severe	NULL
hepatotoxicity	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
GSH	NULL
levels	NULL
in	NULL
the	NULL
liver	NULL
are	NULL
higher	NULL
than	NULL
in	NULL
other	NULL
cells	NULL
may	NULL
explain	NULL
why	NULL
SMX-induced	NULL
hepatotoxicity	NULL
is	NULL
rarely	NULL
observed	NULL
in	NULL
the	NULL
clinical	NULL
situation	NULL
.	NULL

Chemically	NULL
reactive	NULL
products	NULL
of	NULL
oxidative	NULL
drug	NULL
metabolism	NULL
generally	NULL
have	NULL
a	NULL
short	NULL
biological	NULL
half-life	NULL
and	NULL
are	NULL
not	NULL
expected	NULL
to	NULL
reach	NULL
significant	NULL
concentrations	NULL
at	NULL
a	NULL
site	NULL
distant	NULL
from	NULL
where	NULL
they	NULL
are	NULL
formed	NULL
.	NULL

The	NULL
hydroxylamine	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
plasma	NULL
,	NULL
while	NULL
SMX-NO	NULL
can	NULL
not	NULL
,	NULL
reflecting	NULL
the	NULL
instability	NULL
and	NULL
shorter	NULL
half-life	NULL
of	NULL
the	NULL
latter	NULL
.	NULL

1404	NULL
D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
There	NULL
is	NULL
extensive	NULL
reduction	NULL
of	NULL
both	NULL
SMX-NO	NULL
and	NULL
SMX-NHOH	NULL
in	NULL
in	NULL
vivo	NULL
animal	NULL
models	NULL
(	NULL
Gill	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
SMX-NO	NULL
undergoes	NULL
reduction	NULL
in	NULL
plasma	NULL
,	NULL
with	NULL
concomitant	NULL
depletion	NULL
of	NULL
thiols	NULL
in	NULL
vitro	NULL
.	NULL

Thus	NULL
,	NULL
plasma	NULL
concentrations	NULL
of	NULL
CYS	NULL
,	NULL
the	NULL
major	NULL
circulating	NULL
thiol	NULL
[	NULL
total	NULL
levels	NULL
reach	NULL
300	NULL
um	NULL
(	NULL
Mills	NULL
&	NULL
Land	NULL
,	NULL
1996	NULL
)	NULL
]	NULL
in	NULL
blood	NULL
may	NULL
normally	NULL
play	NULL
a	NULL
role	NULL
in	NULL
preventing	NULL
the	NULL
autoxidation	NULL
of	NULL
circulating	NULL
SMX-NHOH	NULL
to	NULL
a	NULL
protein-reactive	NULL
species	NULL
in	NULL
vivo	NULL
.	NULL

Conversely	NULL
,	NULL
a	NULL
disease-induced	NULL
depletion	NULL
of	NULL
plasma	NULL
thiols	NULL
,	NULL
as	NULL
observed	NULL
in	NULL
HIV-positive	NULL
patients	NULL
(	NULL
Eck	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Staal	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Helbling	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Walmsley	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
,	NULL
will	NULL
increase	NULL
the	NULL
possibility	NULL
of	NULL
cell-surface	NULL
haptenation	NULL
and	NULL
thus	NULL
provide	NULL
one	NULL
reason	NULL
for	NULL
the	NULL
greatly	NULL
increased	NULL
incidence	NULL
of	NULL
SMX	NULL
hypersensitivity	NULL
in	NULL
this	NULL
group	NULL
of	NULL
patients	NULL
.	NULL

The	NULL
results	NULL
of	NULL
our	NULL
previous	NULL
study	NULL
demonstrated	NULL
that	NULL
intracellular	NULL
thiols	NULL
,	NULL
principally	NULL
GSH	NULL
,	NULL
can	NULL
effect	NULL
reduction	NULL
of	NULL
SMX-NO	NULL
(	NULL
to	NULL
both	NULL
SMX	NULL
and	NULL
SMX-NHOH	NULL
)	NULL
by	NULL
a	NULL
non-enzymatic	NULL
process	NULL
(	NULL
Naisbitt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
spontaneous	NULL
reaction	NULL
of	NULL
thiols	NULL
with	NULL
hydroxylamines	NULL
and	NULL
nitroso-derivatives	NULL
is	NULL
dependent	NULL
on	NULL
thiol	NULL
concentration	NULL
,	NULL
pH	NULL
and	NULL
the	NULL
electronic	NULL
properties	NULL
of	NULL
the	NULL
aromatic	NULL
ring	NULL
substituents	NULL
of	NULL
the	NULL
drug	NULL
(	NULL
Ellis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
reaction	NULL
is	NULL
initiated	NULL
by	NULL
nucleophilic	NULL
attack	NULL
by	NULL
GSH	NULL
on	NULL
the	NULL
nitroso	NULL
moiety	NULL
resulting	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
an	NULL
unstable	NULL
semi-mercaptal	NULL
intermediate	NULL
which	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
conditions	NULL
,	NULL
can	NULL
yield	NULL
either	NULL
a	NULL
stable	NULL
sulphonamide	NULL
conjugate	NULL
,	NULL
a	NULL
hydroxylamine	NULL
or	NULL
the	NULL
parent	NULL
amine	NULL
(	NULL
Cribb	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Naisbitt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
experiments	NULL
undertaken	NULL
in	NULL
this	NULL
study	NULL
show	NULL
that	NULL
CYS	NULL
is	NULL
also	NULL
capable	NULL
of	NULL
rapid	NULL
and	NULL
complete	NULL
reduction	NULL
of	NULL
SMX-NO	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
rate	NULL
of	NULL
reaction	NULL
was	NULL
more	NULL
rapid	NULL
than	NULL
that	NULL
observed	NULL
with	NULL
equimolar	NULL
concentrations	NULL
of	NULL
GSH	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
reaction	NULL
with	NULL
GSH	NULL
which	NULL
produced	NULL
a	NULL
complex	NULL
series	NULL
of	NULL
reaction	NULL
intermediates	NULL
,	NULL
no	NULL
thiol	NULL
conjugates	NULL
were	NULL
identified	NULL
.	NULL

However	NULL
,	NULL
the	NULL
mechanism	NULL
of	NULL
reduction	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
similar	NULL
.	NULL

The	NULL
thiol/thiolate	NULL
ion	NULL
ratio	NULL
of	NULL
GSH	NULL
and	NULL
CYS	NULL
at	NULL
physiological	NULL
pH	NULL
[	NULL
approximately	NULL
63:1	NULL
(	NULL
GSH/GS~	NULL
)	NULL
;	NULL
8	NULL
:	NULL
1	NULL
(	NULL
CYS/CYS~	NULL
)	NULL
]	NULL
may	NULL
explain	NULL
the	NULL
lack	NULL
of	NULL
conjugate	NULL
formation	NULL
and	NULL
enhanced	NULL
reactivity	NULL
of	NULL
CYS	NULL
towards	NULL
SMX-NO	NULL
(	NULL
Kosower	NULL
&	NULL
Kosower	NULL
,	NULL
1976	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
have	NULL
been	NULL
observed	NULL
by	NULL
other	NULL
groups	NULL
working	NULL
with	NULL
reactive	NULL
electrophiles	NULL
such	NULL
as	NULL
quinones	NULL
,	NULL
diethyl	NULL
maleate	NULL
and	NULL
diethyl	NULL
fumarate	NULL
(	NULL
Murty	NULL
&	NULL
Penning	NULL
,	NULL
1992	NULL
;	NULL
Kubal	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Kubal	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
suggested	NULL
that	NULL
donation	NULL
of	NULL
a	NULL
proton	NULL
from	NULL
the	NULL
amine	NULL
group	NULL
of	NULL
CYS	NULL
may	NULL
enhance	NULL
product	NULL
formation	NULL
,	NULL
while	NULL
in	NULL
turn	NULL
the	NULL
amide	NULL
linkage	NULL
between	NULL
CYS	NULL
and	NULL
glutamate	NULL
in	NULL
GSH	NULL
may	NULL
result	NULL
in	NULL
stabilization	NULL
of	NULL
the	NULL
intermediate	NULL
products	NULL
of	NULL
conjugation	NULL
.	NULL

Intracellular	NULL
reduction	NULL
of	NULL
SMX-NO	NULL
could	NULL
provide	NULL
an	NULL
important	NULL
cellular	NULL
defence	NULL
mechanism	NULL
against	NULL
the	NULL
direct	NULL
toxic	NULL
effects	NULL
of	NULL
the	NULL
metabolite	NULL
.	NULL

We	NULL
therefore	NULL
examined	NULL
the	NULL
metabolism	NULL
of	NULL
SMX-NO	NULL
by	NULL
both	NULL
lymphocytes	NULL
and	NULL
neutrophils	NULL
.	NULL

-	NULL
Cell-concentration	NULL
dependent	NULL
reduction	NULL
of	NULL
SMX-NO	NULL
to	NULL
SMX-NHOH	NULL
was	NULL
observed	NULL
without	NULL
depletion	NULL
of	NULL
intracellular	NULL
GSH	NULL
.	NULL

SMX	NULL
was	NULL
not	NULL
formed	NULL
in	NULL
the	NULL
reaction	NULL
.	NULL

The	NULL
reduction	NULL
was	NULL
blocked	NULL
to	NULL
some	NULL
extent	NULL
by	NULL
specific	NULL
inhibitors	NULL
of	NULL
alcohol	NULL
dehydrogenase	NULL
(	NULL
salicy	NULL
!	NULL

hydroxamate	NULL
,	NULL
NH2	NULL
-SO-NH	NULL
Sulphamethoxazole	NULL
|	NULL
|	NULL
R	NULL
a	NULL
N\O	NULL
CH4	NULL
R	NULL
oxidation	NULL
CYP	NULL
NHOH	NULL
Sulphamethoxazole	NULL
hydroxylamine	NULL
cysteine	NULL
glutathione	NULL
oxidation	NULL
CYP	NULL
N==t	NULL
Nitroso	NULL
l	NULL
sulphamethoxazole	NULL
f	NULL
l	NULL
Cys	NULL
Cell	NULL
NHKﬁ/	NULL
membrane	NULL
Cell	NULL
conjugation	NULL
O	NULL
Figure	NULL
10	NULL
Scheme	NULL
illustrating	NULL
the	NULL
proposed	NULL
mechanism	NULL
of	NULL
SMX	NULL
hypersensitivity	NULL
reactions	NULL
involving	NULL
sequential	NULL
cytochrome	NULL
P450-mediated	NULL
oxidations	NULL
to	NULL
the	NULL
reactive	NULL
nitroso	NULL
metabolite	NULL
which	NULL
can	NULL
bind	NULL
irreversibly	NULL
to	NULL
either	NULL
circulating	NULL
or	NULL
,	NULL
as	NULL
seen	NULL
in	NULL
this	NULL
study	NULL
,	NULL
to	NULL
cell	NULL
surface	NULL
proteins	NULL
,	NULL
to	NULL
elicit	NULL
an	NULL
immune-mediated	NULL
reaction	NULL
.	NULL

Defence	NULL
mechanisms	NULL
involving	NULL
reduction	NULL
of	NULL
the	NULL
reactive	NULL
metabolites	NULL
back	NULL
to	NULL
the	NULL
parent	NULL
compound	NULL
,	NULL
either	NULL
enzymatically	NULL
or	NULL
by	NULL
thiol	NULL
compounds	NULL
,	NULL
are	NULL
also	NULL
indicated	NULL
.	NULL

D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
1405	NULL
dicoumarol	NULL
and	NULL
sodium	NULL
azide	NULL
)	NULL
(	NULL
Somerville	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
an	NULL
enzyme	NULL
previously	NULL
characterized	NULL
in	NULL
human	NULL
neutrophils	NULL
(	NULL
Gotoh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
reductase	NULL
activity	NULL
and	NULL
inhibitor	NULL
studies	NULL
,	NULL
Kuwada	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
and	NULL
others	NULL
(	NULL
Horie	NULL
&	NULL
Ogura	NULL
,	NULL
1980	NULL
)	NULL
have	NULL
also	NULL
demonstrated	NULL
alcohol	NULL
dehydro-genase-dependent	NULL
C-nitroso	NULL
reduction	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
cells	NULL
were	NULL
lysed	NULL
there	NULL
was	NULL
extensive	NULL
consumption	NULL
of	NULL
GSH	NULL
and	NULL
reduction	NULL
of	NULL
SMX-NO	NULL
to	NULL
the	NULL
parent	NULL
amine	NULL
was	NULL
observed	NULL
.	NULL

Thus	NULL
a	NULL
combination	NULL
of	NULL
both	NULL
enzymatic	NULL
and	NULL
non-enzymatic	NULL
processes	NULL
may	NULL
serve	NULL
to	NULL
protect	NULL
cells	NULL
from	NULL
intracellular	NULL
chemical	NULL
damage	NULL
from	NULL
SMX-NO	NULL
.	NULL

These	NULL
findings	NULL
identify	NULL
an	NULL
important	NULL
extrahepatic	NULL
detoxification	NULL
mechanism	NULL
,	NULL
which	NULL
if	NULL
deficient	NULL
,	NULL
may	NULL
determine	NULL
susceptibility	NULL
to	NULL
SMX	NULL
hypersensitivity	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
hepatic	NULL
enzymes	NULL
can	NULL
also	NULL
effect	NULL
the	NULL
reduction	NULL
of	NULL
SMX-NHOH	NULL
to	NULL
SMX	NULL
(	NULL
Cribb	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
;	NULL
an	NULL
NADH-dependent	NULL
hydroxylamine	NULL
reductase	NULL
is	NULL
responsible	NULL
.	NULL

Finally	NULL
,	NULL
there	NULL
is	NULL
the	NULL
question	NULL
of	NULL
cellular	NULL
accumulation	NULL
.	NULL

SMX	NULL
accumulates	NULL
in	NULL
white	NULL
cells	NULL
,	NULL
with	NULL
intracellular	NULL
levels	NULL
increasing	NULL
by	NULL
up	NULL
to	NULL
130	NULL
fold	NULL
in	NULL
infected	NULL
neutrophils	NULL
compared	NULL
with	NULL
resting	NULL
cells	NULL
(	NULL
Climax	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

Intracellular	NULL
accumulation	NULL
,	NULL
together	NULL
with	NULL
inhibition	NULL
of	NULL
neutrophil	NULL
function	NULL
as	NULL
assessed	NULL
by	NULL
inhibition	NULL
of	NULL
eugenol-induced	NULL
GSH	NULL
depletion	NULL
and	NULL
inhibition	NULL
of	NULL
oxidative	NULL
metabolism	NULL
,	NULL
may	NULL
be	NULL
of	NULL
importance	NULL
for	NULL
the	NULL
antimicrobial	NULL
activity	NULL
of	NULL
SMX	NULL
.	NULL

Previous	NULL
studies	NULL
by	NULL
our	NULL
group	NULL
have	NULL
shown	NULL
that	NULL
red	NULL
blood	NULL
cells	NULL
selectively	NULL
accumulate	NULL
dapsone	NULL
hydroxylamine	NULL
(	NULL
Tingle	NULL
&	NULL
Park	NULL
,	NULL
1993	NULL
)	NULL
,	NULL
thus	NULL
providing	NULL
an	NULL
explanation	NULL
for	NULL
the	NULL
cell-selective	NULL
toxicity	NULL
observed	NULL
with	NULL
this	NULL
drug	NULL
;	NULL
i.e	NULL
.	NULL

,	NULL
MetHb	NULL
and	NULL
oxidative	NULL
haemolysis	NULL
.	NULL

Indeed	NULL
,	NULL
circulating	NULL
plasma	NULL
levels	NULL
of	NULL
dapsone	NULL
hydroxylamine	NULL
can	NULL
not	NULL
be	NULL
detected	NULL
(	NULL
Rhodes	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
and	NULL
there	NULL
is	NULL
little	NULL
exposure	NULL
of	NULL
peripheral	NULL
white	NULL
blood	NULL
cells	NULL
to	NULL
this	NULL
toxic	NULL
metabolite	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
SMX-NHOH	NULL
is	NULL
not	NULL
taken	NULL
up	NULL
avidly	NULL
by	NULL
red	NULL
blood	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
differential	NULL
uptake	NULL
by	NULL
red	NULL
blood	NULL
cells	NULL
of	NULL
dapsone	NULL
hydro-	NULL
References	NULL
AKERBOOM	NULL
,	NULL
T.P.M	NULL
.	NULL

&	NULL
SIES	NULL
,	NULL
H.	NULL
(	NULL
1981	NULL
)	NULL
.	NULL

Enzymatic	NULL
and	NULL
non-enzymatic	NULL
assays	NULL
of	NULL
glutathione	NULL
.	NULL

Methods	NULL
in	NULL
Enzymology	NULL
,	NULL
77	NULL
,	NULL
379	NULL
.	NULL

ANGEL	NULL
,	NULL
P.	NULL
&	NULL
KARIN	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
Jun	NULL
,	NULL
Fos	NULL
and	NULL
the	NULL
AP-1	NULL
complex	NULL
in	NULL
cell-proliferation	NULL
and	NULL
transformation	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
.	NULL

,	NULL
1072	NULL
,	NULL
129-157	NULL
.	NULL

ANONYMOUS	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Revised	NULL
indications	NULL
for	NULL
co-trimoxazole	NULL
(	NULL
Septrin	NULL
,	NULL
Bactrim	NULL
,	NULL
various	NULL
genetic	NULL
preparations	NULL
)	NULL
.	NULL

Current	NULL
Problems	NULL
in	NULL
Pharmacovigilance	NULL
,	NULL
21	NULL
,	NULL
6	NULL
.	NULL

BAEUERLE	NULL
,	NULL
P.A	NULL
.	NULL

&	NULL
HENKEL	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Function	NULL
and	NULL
activation	NULL
of	NULL
NF-xB	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
141-179	NULL
.	NULL

BLAZKA	NULL
,	NULL
ME	NULL
.	NULL

,	NULL
BRUCCOLERI	NULL
,	NULL
A.	NULL
,	NULL
SIMEONOYA	NULL
,	NULL
P.	NULL
,	NULL
GERMOLEC	NULL
,	NULL
D.R	NULL
.	NULL

,	NULL
PENNYPACKER	NULL
,	NULL
K.R	NULL
.	NULL

&	NULL
LUSTER	NULL
,	NULL
ML	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Acetamino-phen-induced	NULL
hepatotoxicity	NULL
is	NULL
associated	NULL
with	NULL
early	NULL
changes	NULL
in	NULL
AP-1	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

Res	NULL
.	NULL

Comm	NULL
.	NULL

Mol	NULL
.	NULL

Pathol	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
92	NULL
,	NULL
259-273	NULL
.	NULL

BLAZKA	NULL
,	NULL
ME	NULL
.	NULL

,	NULL
GERMOLEC	NULL
,	NULL
D.R	NULL
.	NULL

,	NULL
SIMEONOYA	NULL
,	NULL
P.	NULL
,	NULL
BRUCCOLERI	NULL
,	NULL
A.	NULL
,	NULL
PENNYPACKER	NULL
,	NULL
KR	NULL
.	NULL

&	NULL
LUSTER	NULL
,	NULL
ML	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Acetamino-phen-induced	NULL
hepatotoxicity	NULL
is	NULL
associated	NULL
with	NULL
early	NULL
changes	NULL
in	NULL
NF-xB	NULL
and	NULL
NF-IL6	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

J	NULL
.	NULL

Inflamm	NULL
.	NULL

,	NULL
47	NULL
,	NULL
138	NULL
150	NULL
.	NULL

CARR	NULL
,	NULL
A	NULL
.	NULL

&	NULL
COOPER	NULL
,	NULL
D.A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Pathogenesis	NULL
and	NULL
management	NULL
of	NULL
HIV-associated	NULL
drug	NULL
hypersensitivity	NULL
.	NULL

AIDS	NULL
Clin	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
96	NULL
,	NULL
65-97	NULL
.	NULL

CARR	NULL
,	NULL
A.	NULL
,	NULL
TINDALL	NULL
,	NULL
B.	NULL
,	NULL
PENNY	NULL
,	NULL
R.	NULL
&	NULL
COOPER	NULL
,	NULL
D.A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
cytotoxicity	NULL
as	NULL
a	NULL
marker	NULL
of	NULL
hypersensitivity	NULL
to	NULL
sulphamethoxazole	NULL
in	NULL
patients	NULL
with	NULL
HIV	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
94	NULL
,	NULL
21-25	NULL
.	NULL

CLIMAX	NULL
,	NULL
J.	NULL
,	NULL
LENEHAN	NULL
,	NULL
T.J.	NULL
,	NULL
LAMBE	NULL
,	NULL
R.	NULL
,	NULL
KENNY	NULL
,	NULL
M.	NULL
,	NULL
CAFFREY	NULL
,	NULL
E.	NULL
&	NULL
DAARRAGH	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
.	NULL

Interaction	NULL
of	NULL
antibacterial	NULL
agents	NULL
with	NULL
human	NULL
peripheral	NULL
blood	NULL
leucocytes	NULL
:	NULL
Uptake	NULL
and	NULL
intracellular	NULL
localisation	NULL
of	NULL
certain	NULL
sulphonamides	NULL
and	NULL
trimethoprims	NULL
.	NULL

J.	NULL
Antimicrob	NULL
.	NULL

Agents	NULL
Chemother	NULL
.	NULL

,	NULL
17	NULL
,	NULL
489-498.	NULL
xylamine	NULL
may	NULL
serve	NULL
to	NULL
protect	NULL
against	NULL
hypersensitivity	NULL
,	NULL
and	NULL
thus	NULL
provide	NULL
one	NULL
reason	NULL
for	NULL
the	NULL
markedly	NULL
different	NULL
clinical	NULL
toxicological	NULL
profiles	NULL
of	NULL
the	NULL
two	NULL
structurally	NULL
related	NULL
anti-infectives	NULL
,	NULL
SMX	NULL
and	NULL
dapsone	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
in	NULL
an	NULL
in	NULL
vitro	NULL
model	NULL
,	NULL
the	NULL
propensity	NULL
of	NULL
a	NULL
metabolite	NULL
of	NULL
SMX	NULL
,	NULL
SMX-NO	NULL
,	NULL
to	NULL
haptenate	NULL
cell-surface	NULL
proteins	NULL
on	NULL
viable	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
under	NULL
normal	NULL
physiological	NULL
conditions	NULL
a	NULL
number	NULL
of	NULL
processes	NULL
would	NULL
serve	NULL
to	NULL
prevent	NULL
such	NULL
chemical	NULL
modification	NULL
of	NULL
autologous	NULL
cells	NULL
,	NULL
with	NULL
endogenous	NULL
thiols	NULL
playing	NULL
a	NULL
key	NULL
role	NULL
in	NULL
drug	NULL
metabolite	NULL
detoxication	NULL
(	NULL
Figure	NULL
10	NULL
)	NULL
.	NULL

However	NULL
,	NULL
if	NULL
the	NULL
normal	NULL
balance	NULL
between	NULL
drug	NULL
bioactivation	NULL
and	NULL
metabolite	NULL
bioinactivation	NULL
,	NULL
both	NULL
hepatic	NULL
and	NULL
peripheral	NULL
,	NULL
is	NULL
disturbed	NULL
,	NULL
haptenation	NULL
of	NULL
cell	NULL
surfaces	NULL
could	NULL
lead	NULL
to	NULL
an	NULL
immune	NULL
response	NULL
.	NULL

Such	NULL
observations	NULL
are	NULL
of	NULL
particular	NULL
relevance	NULL
to	NULL
AIDS	NULL
patients	NULL
who	NULL
require	NULL
treatment	NULL
with	NULL
this	NULL
drug	NULL
despite	NULL
its	NULL
adverse	NULL
reaction	NULL
profile	NULL
,	NULL
and	NULL
in	NULL
whom	NULL
the	NULL
detoxication	NULL
processes	NULL
of	NULL
glucuronidation	NULL
(	NULL
Esteban	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
,	NULL
acetylation	NULL
(	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
and	NULL
reduction	NULL
by	NULL
thiols	NULL
(	NULL
Naisbitt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
unpublished	NULL
observation	NULL
)	NULL
are	NULL
known	NULL
to	NULL
be	NULL
impaired	NULL
.	NULL

Studies	NULL
are	NULL
underway	NULL
to	NULL
measure	NULL
cell	NULL
haptenation	NULL
in	NULL
such	NULL
patients	NULL
with	NULL
,	NULL
and	NULL
without	NULL
,	NULL
hypersensitivity	NULL
.	NULL

The	NULL
authors	NULL
would	NULL
like	NULL
to	NULL
express	NULL
their	NULL
thanks	NULL
to	NULL
Miss	NULL
Helen	NULL
Powell	NULL
,	NULL
Dr	NULL
James	NULL
Maggs	NULL
and	NULL
Dr	NULL
Stephen	NULL
Madden	NULL
for	NULL
assistance	NULL
with	NULL
molecular	NULL
biology	NULL
,	NULL
mass	NULL
spectrometry	NULL
and	NULL
analytical	NULL
techniques	NULL
respectively	NULL
.	NULL

We	NULL
also	NULL
acknowledge	NULL
the	NULL
Depts	NULL
.	NULL

of	NULL
Immunology	NULL
and	NULL
Veterinary	NULL
Pathology	NULL
(	NULL
The	NULL
University	NULL
of	NULL
Liverpool	NULL
)	NULL
for	NULL
use	NULL
of	NULL
their	NULL
flow	NULL
cytometers	NULL
.	NULL

Anti-SMX	NULL
IgG	NULL
antibody	NULL
was	NULL
kindly	NULL
donated	NULL
by	NULL
Dr	NULL
A.E	NULL
.	NULL

Cribb	NULL
(	NULL
Merck	NULL
Research	NULL
Laboratories	NULL
,	NULL
West	NULL
Point	NULL
,	NULL
PA	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Thanks	NULL
are	NULL
also	NULL
extended	NULL
to	NULL
the	NULL
Wellcome	NULL
Trust	NULL
,	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
and	NULL
the	NULL
NHS	NULL
Executive	NULL
North	NULL
West	NULL
(	NULL
grant	NULL
RDO/25/19	NULL
)	NULL
for	NULL
funding	NULL
PhD	NULL
studentships	NULL
.	NULL

B.K.P	NULL
.	NULL

is	NULL
a	NULL
Wellcome	NULL
Principal	NULL
Fellow	NULL
.	NULL

COTGREAVE	NULL
,	NULL
LA	NULL
.	NULL

&	NULL
MOLDEUS	NULL
,	NULL
P.	NULL
(	NULL
1986	NULL
)	NULL
.	NULL

Methodologies	NULL
for	NULL
the	NULL
application	NULL
of	NULL
monobromobimane	NULL
to	NULL
the	NULL
simultaneous	NULL
analysis	NULL
of	NULL
soluble	NULL
and	NULL
protein	NULL
bound	NULL
thiol	NULL
components	NULL
of	NULL
biological	NULL
systems	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Methods	NULL
,	NULL
13	NULL
,	NULL
231-249	NULL
.	NULL

COX	NULL
,	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Glucocorticoid	NULL
treatment	NULL
inhibits	NULL
apoptosis	NULL
in	NULL
human	NULL
neutrophils	NULL
-	NULL
separation	NULL
of	NULL
survival	NULL
and	NULL
activation	NULL
outcomes	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
154	NULL
,	NULL
4719-4725	NULL
.	NULL

CRIBB	NULL
,	NULL
A.E	NULL
.	NULL

,	NULL
LEE	NULL
,	NULL
B.L	NULL
.	NULL

,	NULL
TREPANIER	NULL
,	NULL
L.A.	NULL
&	NULL
SPEILBERG	NULL
,	NULL
S.P	NULL
.	NULL

(	NULL
19962	NULL
)	NULL
.	NULL

Adverse	NULL
reactions	NULL
to	NULL
sulphonamide	NULL
and	NULL
sulphonamide-trimetho-prim	NULL
antimicrobials	NULL
.	NULL

Clinical	NULL
syndromes	NULL
and	NULL
pathogenesis	NULL
.	NULL

Adv	NULL
.	NULL

Drug	NULL
React	NULL
.	NULL

Toxicol	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
15	NULL
,	NULL
9-50	NULL
.	NULL

CRIBB	NULL
,	NULL
A.E	NULL
.	NULL

,	NULL
MILLER	NULL
,	NULL
M.	NULL
,	NULL
LEEDER	NULL
,	NULL
J.S	NULL
.	NULL

,	NULL
HILL	NULL
,	NULL
J	NULL
.	NULL

&	NULL
SPIELBERG	NULL
,	NULL
SIP	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Reactions	NULL
of	NULL
nitroso	NULL
and	NULL
hydroxylamine	NULL
metabolites	NULL
of	NULL
sulphamethoxazole	NULL
with	NULL
reduced	NULL
glutathione	NULL
:	NULL
implications	NULL
for	NULL
idiosyncratic	NULL
toxicity	NULL
.	NULL

Drug	NULL
.	NULL

Metab	NULL
.	NULL

Dispos	NULL
.	NULL

,	NULL
19	NULL
,	NULL
900-906	NULL
.	NULL

CRIBB	NULL
,	NULL
A.E	NULL
.	NULL

,	NULL
MILLER	NULL
,	NULL
M.	NULL
,	NULL
TESORO	NULL
,	NULL
A	NULL
.	NULL

&	NULL
SPIELBERG	NULL
,	NULL
S.P	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Peroxidase-dependent	NULL
oxidation	NULL
of	NULL
sulfonamides	NULL
by	NULL
monocytes	NULL
and	NULL
neutrophils	NULL
from	NULL
humans	NULL
and	NULL
dogs	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
38	NULL
,	NULL
744-751	NULL
.	NULL

CRIBB	NULL
,	NULL
A.E	NULL
.	NULL

,	NULL
NUSS	NULL
,	NULL
C.E	NULL
.	NULL

,	NULL
ALBERTS	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
LAMPHERE	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
GRANT	NULL
,	NULL
D.M	NULL
.	NULL

,	NULL
GROSSMAN	NULL
,	NULL
$	NULL
.J	NULL
.	NULL

&	NULL
SPIELBERG	NULL
,	NULL
S.P	NULL
.	NULL

(	NULL
1996b	NULL
)	NULL
.	NULL

Covalent	NULL
binding	NULL
of	NULL
sulphamethoxazole	NULL
reactive	NULL
metabolites	NULL
to	NULL
human	NULL
and	NULL
rat	NULL
liver	NULL
subcellular	NULL
fractions	NULL
assessed	NULL
by	NULL
immunochemical	NULL
detection	NULL
.	NULL

Chem	NULL
.	NULL

Res	NULL
.	NULL

Toxicol	NULL
.	NULL

,	NULL
9	NULL
,	NULL
500-507	NULL
.	NULL

CRIBB	NULL
,	NULL
AE	NULL
.	NULL

,	NULL
SPIELBERG	NULL
,	NULL
S.P	NULL
.	NULL

&	NULL
GRIFFIN	NULL
,	NULL
GP	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
N	NULL
,	NULL
-hydroxylation	NULL
of	NULL
sulfamethoxazole	NULL
by	NULL
cytochrome	NULL
P450	NULL
of	NULL
the	NULL
cytochrome	NULL
P4502C	NULL
subfamily	NULL
and	NULL
reduction	NULL
of	NULL
sulfamethoxazole	NULL
hydroxylamine	NULL
in	NULL
human	NULL
and	NULL
rat	NULL
hepatic	NULL
microsomes	NULL
.	NULL

Drug	NULL
Metab	NULL
.	NULL

Dispos	NULL
.	NULL

,	NULL
23	NULL
,	NULL
406-414	NULL
.	NULL

1406	NULL
D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
DAFTARIAN	NULL
,	NULL
M.P	NULL
.	NULL

,	NULL
FILION	NULL
,	NULL
LG	NULL
.	NULL

,	NULL
CAMERON	NULL
,	NULL
W.	NULL
,	NULL
CONWAY	NULL
,	NULL
B.	NULL
,	NULL
ROY	NULL
,	NULL
R.	NULL
,	NULL
TROOPER	NULL
,	NULL
F.	NULL
&	NULL
DIAZ-MITOMA	NULL
,	NULL
F.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Immune	NULL
response	NULL
to	NULL
sulphamethoxazole	NULL
in	NULL
patients	NULL
with	NULL
AIDS	NULL
.	NULL

C/im	NULL
.	NULL

Diagnostic	NULL
Lab	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
2	NULL
,	NULL
199-204	NULL
.	NULL

ECK	NULL
,	NULL
H.P	NULL
.	NULL

,	NULL
GMUNDER	NULL
,	NULL
H.	NULL
,	NULL
PETZOLDT	NULL
,	NULL
D.	NULL
,	NULL
DANIEL	NULL
,	NULL
V.	NULL
&	NULL
DROGE	NULL
,	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Low	NULL
concentrations	NULL
of	NULL
acid	NULL
soluble	NULL
thiol	NULL
in	NULL
the	NULL
plasma	NULL
of	NULL
HIV-1	NULL
infected	NULL
patients	NULL
.	NULL

Biol	NULL
.	NULL

Chem	NULL
.	NULL

Hoppe-Seyler	NULL
,	NULL
370	NULL
,	NULL
101	NULL
108	NULL
.	NULL

ELLIS	NULL
,	NULL
MK	NULL
.	NULL

,	NULL
HILL	NULL
,	NULL
S.	NULL
&	NULL
FOSTER	NULL
,	NULL
P.M.D	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Reactions	NULL
of	NULL
nitrosobenzenes	NULL
with	NULL
biological	NULL
thiols	NULL
:	NULL
Identification	NULL
and	NULL
reactivity	NULL
of	NULL
glutathion-S-yl	NULL
conjugates	NULL
.	NULL

Chem	NULL
.	NULL

Biol	NULL
.	NULL

Interact	NULL
.	NULL

,	NULL
82	NULL
,	NULL
151-163	NULL
.	NULL

ESTEBAN	NULL
,	NULL
A.	NULL
,	NULL
PEREZMATEO	NULL
,	NULL
M.	NULL
,	NULL
BOIX	NULL
,	NULL
V.	NULL
,	NULL
GONZALEZ	NULL
,	NULL
M.	NULL
,	NULL
PORTILLA	NULL
,	NULL
M.	NULL
&	NULL
MORA	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Abnormalities	NULL
in	NULL
the	NULL
metabolism	NULL
of	NULL
acetaminophen	NULL
in	NULL
patients	NULL
infected	NULL
with	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
.	NULL

Methods	NULL
Findings	NULL
Exp	NULL
.	NULL

Clin	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
19	NULL
,	NULL
129-132	NULL
.	NULL

GILL	NULL
,	NULL
H.J	NULL
.	NULL

,	NULL
HOUGH	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
NAISBITT	NULL
,	NULL
DJ	NULL
.	NULL

,	NULL
PIRMOHAMED	NULL
,	NULL
M.	NULL
,	NULL
KITTERINGHAM	NULL
,	NULL
N.R	NULL
.	NULL

&	NULL
PARK	NULL
,	NULL
BK	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

The	NULL
relationship	NULL
between	NULL
the	NULL
disposition	NULL
and	NULL
the	NULL
immunogenicity	NULL
of	NULL
sulphamethoxazole	NULL
in	NULL
the	NULL
rat	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

,	NULL
282	NULL
,	NULL
1375-1382	NULL
.	NULL

GILL	NULL
,	NULL
H.J	NULL
.	NULL

,	NULL
MAGGS	NULL
,	NULL
J.L	NULL
.	NULL

,	NULL
MADDEN	NULL
,	NULL
$	NULL
.	NULL

,	NULL
PIRMOHAMED	NULL
,	NULL
M.	NULL
&	NULL
PARK	NULL
,	NULL
B.K	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
fluconazole	NULL
and	NULL
ketoconazole	NULL
on	NULL
the	NULL
metabolism	NULL
of	NULL
sulphamethoxazole	NULL
.	NULL

Br	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
42	NULL
,	NULL
347-353	NULL
.	NULL

GOTOH	NULL
,	NULL
Y.	NULL
,	NULL
SUMIMOTO	NULL
,	NULL
H.	NULL
&	NULL
MINAKAML	NULL
,	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Formation	NULL
of	NULL
20-oxoleukotrine	NULL
B4	NULL
by	NULL
an	NULL
alcohol	NULL
dehydrogenase	NULL
isolated	NULL
from	NULL
human	NULL
neutrophils	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
.	NULL

,	NULL
1043	NULL
,	NULL
52-56	NULL
.	NULL

HARRISON	NULL
,	NULL
J.H	NULL
.	NULL

&	NULL
JOLLOW	NULL
,	NULL
D.J	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
.	NULL

Role	NULL
of	NULL
aniline	NULL
metabolites	NULL
in	NULL
aniline-induced	NULL
haemolytic	NULL
anaemia	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

,	NULL
238	NULL
,	NULL
1045-1054	NULL
.	NULL

HASTINGS	NULL
,	NULL
K.L	NULL
.	NULL

,	NULL
THOMAS	NULL
,	NULL
C.	NULL
,	NULL
BROWN	NULL
,	NULL
A.P	NULL
.	NULL

&	NULL
GANDOLFI	NULL
,	NULL
AJ	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Trifluoroacetylation	NULL
potentiates	NULL
the	NULL
humoral	NULL
response	NULL
to	NULL
halothane	NULL
in	NULL
the	NULL
guinea	NULL
pig	NULL
.	NULL

Immunopharm	NULL
.	NULL

Immunotox	NULL
.	NULL

,	NULL
17	NULL
,	NULL
201-213	NULL
.	NULL

HELBLING	NULL
,	NULL
B.	NULL
,	NULL
VON	NULL
OVERBECK	NULL
,	NULL
J	NULL
.	NULL

&	NULL
LAUTERBURG	NULL
,	NULL
B.H	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Decreased	NULL
release	NULL
of	NULL
glutathione	NULL
into	NULL
the	NULL
systemic	NULL
circulation	NULL
of	NULL
patients	NULL
with	NULL
HIV	NULL
infection	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
26	NULL
,	NULL
38-44	NULL
.	NULL

HORIE	NULL
,	NULL
$	NULL
.	NULL

&	NULL
OGURA	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
.	NULL

Studies	NULL
on	NULL
the	NULL
enzymatic	NULL
reduction	NULL
of	NULL
C-nitroso	NULL
compounds	NULL
.	NULL

IV	NULL
.	NULL

Partial	NULL
purification	NULL
and	NULL
kinetic	NULL
properties	NULL
of	NULL
porcine	NULL
heart	NULL
C-nitrosoreductase	NULL
.	NULL

J	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
88	NULL
,	NULL
1141-1150	NULL
.	NULL

KOOPMANS	NULL
,	NULL
P.P	NULL
.	NULL

,	NULL
VAN	NULL
DER	NULL
VEN	NULL
,	NULL
A.J.A.M	NULL
.	NULL

,	NULL
VREE	NULL
,	NULL
T.B	NULL
.	NULL

&	NULL
VAN	NULL
DER	NULL
MEER	NULL
,	NULL
J.W.M	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Pathogenesis	NULL
of	NULL
hypersensitivity	NULL
reactions	NULL
to	NULL
drugs	NULL
in	NULL
patients	NULL
with	NULL
HIV	NULL
infection	NULL
:	NULL
allergic	NULL
or	NULL
toxic	NULL
?	NULL

AIDS	NULL
,	NULL
9	NULL
,	NULL
217-222	NULL
.	NULL

KOSOWER	NULL
,	NULL
N.S	NULL
.	NULL

&	NULL
KOSOWER	NULL
,	NULL
EM	NULL
.	NULL

(	NULL
1976	NULL
)	NULL
.	NULL

Functional	NULL
aspects	NULL
of	NULL
glutathione	NULL
disulphides	NULL
and	NULL
hidden	NULL
forms	NULL
of	NULL
glutathione	NULL
,	NULL
In	NULL
Glutathione	NULL
:	NULL
Metabolism	NULL
and	NULL
Function	NULL
.	NULL

ed	NULL
.	NULL

Arias	NULL
,	NULL
LM	NULL
.	NULL

&	NULL
Jakoby	NULL
,	NULL
W.B	NULL
.	NULL

pp	NULL
.	NULL

159-174	NULL
,	NULL
Raven	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
.	NULL

KUBAL	NULL
,	NULL
G.	NULL
,	NULL
MEYER	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
NORMAN	NULL
,	NULL
RE	NULL
.	NULL

&	NULL
SADLER	NULL
,	NULL
P.J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Investigations	NULL
of	NULL
glutathione	NULL
conjugation	NULL
in	NULL
vitro	NULL
by	NULL
1H	NULL
NMR	NULL
spectroscopy	NULL
.	NULL

Uncatalysed	NULL
and	NULL
glutathione	NULL
transferase-catalysed	NULL
reactions	NULL
.	NULL

Chem	NULL
.	NULL

Res	NULL
.	NULL

Toxicol	NULL
.	NULL

,	NULL
8	NULL
,	NULL
780-791	NULL
.	NULL

KUWADA	NULL
,	NULL
M.	NULL
,	NULL
HORIE	NULL
,	NULL
S.	NULL
&	NULL
OGURA	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
.	NULL

Studies	NULL
on	NULL
the	NULL
enzymatic	NULL
reduction	NULL
of	NULL
C-nitroso	NULL
compounds	NULL
.	NULL

II	NULL
.	NULL

Multiple	NULL
forms	NULL
of	NULL
liver	NULL
C-nitrosoreductase	NULL
and	NULL
the	NULL
identity	NULL
with	NULL
alcohol	NULL
dehydrogenase	NULL
.	NULL

J	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
88	NULL
,	NULL
859-869	NULL
.	NULL

LAWRENCE	NULL
,	NULL
D.A	NULL
.	NULL

,	NULL
SONG	NULL
,	NULL
R.	NULL
&	NULL
WEBER	NULL
,	NULL
P.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Surface	NULL
thiols	NULL
of	NULL
human	NULL
lymphocytes	NULL
and	NULL
their	NULL
changes	NULL
after	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
activation	NULL
.	NULL

J.	NULL
Leukoc	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
60	NULL
,	NULL
611-618	NULL
.	NULL

LEE	NULL
,	NULL
BL	NULL
.	NULL

,	NULL
WONG	NULL
,	NULL
D.	NULL
,	NULL
BENOWITZ	NULL
,	NULL
N.L	NULL
.	NULL

&	NULL
SULLAM	NULL
,	NULL
P.M.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Altered	NULL
patterns	NULL
of	NULL
drug	NULL
metabolism	NULL
in	NULL
patients	NULL
with	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
.	NULL

Clin	NULL
.	NULL

Pharmacol	NULL
.	NULL

Ther	NULL
.	NULL

,	NULL
53	NULL
,	NULL
529-535	NULL
.	NULL

MANDELL	NULL
,	NULL
G.L	NULL
.	NULL

&	NULL
SANDE	NULL
,	NULL
M.A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
.	NULL

Anti-microbial	NULL
agents	NULL
:	NULL
Sulfonamides	NULL
,	NULL
trimethoprim-sulfamethoxazole	NULL
and	NULL
agents	NULL
for	NULL
urinary	NULL
tract	NULL
infections	NULL
,	NULL
In	NULL
The	NULL
Pharmacological	NULL
Basis	NULL
of	NULL
Therapeutics	NULL
.	NULL

ed	NULL
Gilman	NULL
,	NULL
A.G.	NULL
,	NULL
Goodman	NULL
,	NULL
L.S	NULL
.	NULL

,	NULL
Rall	NULL
,	NULL
TW	NULL
.	NULL

&	NULL
Marud	NULL
,	NULL
R.	NULL
pp.1095-1114	NULL
,	NULL
Macmillan	NULL
Publishing	NULL
Co.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

MAURI-HELLWEG	NULL
,	NULL
D.	NULL
,	NULL
BETTENS	NULL
,	NULL
F.	NULL
,	NULL
MAURI	NULL
,	NULL
D.	NULL
,	NULL
BRANDER	NULL
,	NULL
C.	NULL
,	NULL
HUNZIKER	NULL
,	NULL
T.	NULL
&	NULL
PICHLER	NULL
,	NULL
W.J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
drug	NULL
specific	NULL
CD4+	NULL
and	NULL
CD8+	NULL
T	NULL
cells	NULL
in	NULL
individuals	NULL
allergic	NULL
to	NULL
sulphonamides	NULL
,	NULL
phenytoin	NULL
,	NULL
and	NULL
carbamazepine	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
155	NULL
,	NULL
462-472	NULL
.	NULL

MEEKINS	NULL
,	NULL
C.V.	NULL
,	NULL
SULIVAN	NULL
,	NULL
TJ	NULL
.	NULL

&	NULL
GRUCHALLA	NULL
,	NULL
RS	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Immunological	NULL
analysis	NULL
of	NULL
sulphonamide	NULL
drug	NULL
allergy	NULL
:	NULL
identification	NULL
of	NULL
sulphamethoxazole	NULL
substituted	NULL
human	NULL
serum	NULL
proteins	NULL
.	NULL

J	NULL
.	NULL

Allergy	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
94	NULL
,	NULL
1017-1024	NULL
.	NULL

MILLS	NULL
,	NULL
B.J	NULL
.	NULL

&	NULL
LANG	NULL
,	NULL
C.A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Differential	NULL
distribution	NULL
of	NULL
free	NULL
and	NULL
bound	NULL
glutathione	NULL
and	NULL
cyst	NULL
(	NULL
e	NULL
)	NULL
ine	NULL
in	NULL
human	NULL
blood	NULL
.	NULL

Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
52	NULL
,	NULL
401-406	NULL
.	NULL

MITRA	NULL
,	NULL
A.K	NULL
.	NULL

,	NULL
THUMMEL	NULL
,	NULL
K.E	NULL
.	NULL

,	NULL
KALHORN	NULL
,	NULL
T.F	NULL
.	NULL

,	NULL
KHARASCH	NULL
,	NULL
ED	NULL
.	NULL

,	NULL
UNADKAT	NULL
,	NULL
J.D	NULL
.	NULL

&	NULL
SLATTERY	NULL
,	NULL
J.T	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
sulfamethoxazole	NULL
hydroxylamine	NULL
formation	NULL
by	NULL
fluconazole	NULL
in	NULL
human	NULL
liver	NULL
microsomes	NULL
and	NULL
healthy	NULL
volunteers	NULL
.	NULL

C/in	NULL
.	NULL

Pharmacol	NULL
.	NULL

Therap	NULL
.	NULL

,	NULL
59	NULL
,	NULL
332-340	NULL
.	NULL

MURTY	NULL
,	NULL
V.S	NULL
.	NULL

&	NULL
PENNING	NULL
,	NULL
TM	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Polycyclic	NULL
aromatic	NULL
hydrocarbon	NULL
(	NULL
PAH	NULL
)	NULL
ortho-quinone	NULL
conjugate	NULL
chemistry	NULL
:	NULL
kinetics	NULL
of	NULL
thiol	NULL
addition	NULL
of	NULL
PAH	NULL
ortho-quinones	NULL
and	NULL
structures	NULL
of	NULL
thioether	NULL
adducts	NULL
of	NULL
naphthalene-1,2-dione	NULL
.	NULL

Chem	NULL
.	NULL

Biol	NULL
.	NULL

Interact	NULL
.	NULL

,	NULL
84	NULL
,	NULL
169-188	NULL
.	NULL

NAISBITT	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
O'NEILL	NULL
,	NULL
P.M.	NULL
,	NULL
PIRMOHAMED	NULL
,	NULL
M.	NULL
&	NULL
PARK	NULL
,	NULL
BK	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Synthesis	NULL
and	NULL
reactions	NULL
of	NULL
nitroso	NULL
sulphamethoxazole	NULL
with	NULL
biological	NULL
nucleophiles	NULL
:	NULL
Implications	NULL
for	NULL
immune-mediated	NULL
toxicity	NULL
.	NULL

Bioorg	NULL
.	NULL

Med	NULL
.	NULL

Chem	NULL
.	NULL

Let	NULL
.	NULL

,	NULL
6	NULL
,	NULL
1511-1516	NULL
.	NULL

NAISBITT	NULL
,	NULL
DJ	NULL
.	NULL

,	NULL
RUSCOE	NULL
,	NULL
J.E	NULL
.	NULL

,	NULL
WILLIAMS	NULL
,	NULL
D.P	NULL
.	NULL

,	NULL
O'NEILL	NULL
,	NULL
P.M.	NULL
,	NULL
PIRMOHAMED	NULL
,	NULL
M.	NULL
&	NULL
PARK	NULL
,	NULL
BK	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Disposition	NULL
of	NULL
amodiaquine	NULL
and	NULL
related	NULL
antimalarials	NULL
in	NULL
human	NULL
neutrophils	NULL
:	NULL
Implications	NULL
for	NULL
drug	NULL
design	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

,	NULL
280	NULL
,	NULL
884-893	NULL
.	NULL

NICOLETTI	NULL
,	NULL
I.	NULL
,	NULL
MIGLIORATI	NULL
,	NULL
G.	NULL
,	NULL
PAGLIACCI	NULL
,	NULL
M.C	NULL
.	NULL

,	NULL
GRIGNANI	NULL
,	NULL
F.	NULL
&	NULL
RICARDI	NULL
,	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

A	NULL
rapid	NULL
and	NULL
simple	NULL
method	NULL
for	NULL
measuring	NULL
thymocyte	NULL
apoptosis	NULL
by	NULL
propidium	NULL
iodide	NULL
staining	NULL
and	NULL
flow	NULL
cytometry	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
,	NULL
139	NULL
,	NULL
271-276	NULL
.	NULL

PARK	NULL
,	NULL
B.K	NULL
.	NULL

,	NULL
PIRMOHAMED	NULL
,	NULL
M.	NULL
&	NULL
KITTERINGHAM	NULL
,	NULL
N.R	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
drug	NULL
disposition	NULL
in	NULL
drug	NULL
hypersensitivity	NULL
:	NULL
A	NULL
chemical	NULL
,	NULL
molecular	NULL
and	NULL
clinical	NULL
perspective	NULL
.	NULL

Chem	NULL
.	NULL

Res	NULL
.	NULL

Toxicol	NULL
.	NULL

,	NULL
11	NULL
,	NULL
969	NULL
988	NULL
.	NULL

PIRMOHAMED	NULL
,	NULL
M.	NULL
,	NULL
COLEMAN	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
HUSSAIN	NULL
,	NULL
F.	NULL
,	NULL
BRECKEN	NULL
:	NULL
-RIDGE	NULL
,	NULL
A.M.	NULL
&	NULL
PARK	NULL
,	NULL
BK	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Direct	NULL
and	NULL
metabolism	NULL
dependent	NULL
toxicity	NULL
of	NULL
sulphasalazine	NULL
and	NULL
its	NULL
principal	NULL
metabolite	NULL
towards	NULL
human	NULL
erythrocytes	NULL
and	NULL
leucocytes	NULL
.	NULL

Br	NULL
.	NULL

J.	NULL
C/in	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
32	NULL
,	NULL
303-310	NULL
.	NULL

PIRMOHAMED	NULL
,	NULL
M.	NULL
&	NULL
PARK	NULL
,	NULL
BK	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Drug	NULL
reactions	NULL
in	NULL
HIV-infected	NULL
patients	NULL
.	NULL

Postgrad	NULL
.	NULL

Doctor	NULL
,	NULL
18	NULL
,	NULL
438-444	NULL
.	NULL

PIRMOHAMED	NULL
,	NULL
M.	NULL
,	NULL
WILLIAMS	NULL
,	NULL
D.P	NULL
.	NULL

,	NULL
TINGLE	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
BARRY	NULL
,	NULL
M.	NULL
,	NULL
KHOO	NULL
,	NULL
$	NULL
.	NULL

,	NULL
O'MAHONY	NULL
,	NULL
C.	NULL
,	NULL
WILKINS	NULL
,	NULL
E.	NULL
,	NULL
BRECKENRIDGE	NULL
,	NULL
A.M.	NULL
&	NULL
PARK	NULL
,	NULL
B.K	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Intracellular	NULL
glutathione	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
cells	NULL
of	NULL
HIV-infected	NULL
patients	NULL
:	NULL
failure	NULL
to	NULL
show	NULL
a	NULL
deficiency	NULL
.	NULL

AIDS	NULL
,	NULL
10	NULL
,	NULL
501-507	NULL
.	NULL

RAFFRAY	NULL
,	NULL
M.	NULL
&	NULL
COHEN	NULL
,	NULL
G.M	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Apoptosis	NULL
and	NULL
necrosis	NULL
in	NULL
toxicology	NULL
:	NULL
A	NULL
continuum	NULL
or	NULL
distinct	NULL
modes	NULL
of	NULL
cell	NULL
death	NULL
?	NULL

Pharmacol	NULL
.	NULL

Ther	NULL
.	NULL

,	NULL
75	NULL
,	NULL
153-177	NULL
.	NULL

RHODES	NULL
,	NULL
LE	NULL
.	NULL

,	NULL
TINGLE	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
PARK	NULL
,	NULL
B.K	NULL
.	NULL

,	NULL
CHU	NULL
,	NULL
P.	NULL
,	NULL
VERBOY	NULL
,	NULL
J.L	NULL
.	NULL

&	NULL
FRIEDMANN	NULL
,	NULL
P.S	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Cimetidine	NULL
improves	NULL
the	NULL
therapeutic	NULL
toxic	NULL
ratio	NULL
of	NULL
dapsone	NULL
in	NULL
patients	NULL
on	NULL
chronic	NULL
dapsone	NULL
therapy	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Dermotol	NULL
.	NULL

,	NULL
132	NULL
,	NULL
257-262	NULL
.	NULL

RIEDER	NULL
,	NULL
M.J.	NULL
,	NULL
KRAUSE	NULL
,	NULL
R.	NULL
&	NULL
BIRD	NULL
,	NULL
LA	NULL
.	NULL

(	NULL
1995a	NULL
)	NULL
.	NULL

Time-course	NULL
of	NULL
toxicity	NULL
of	NULL
reactive	NULL
sulphonamide	NULL
metabolites	NULL
.	NULL

Toxicology	NULL
,	NULL
95	NULL
,	NULL
141-146	NULL
.	NULL

RIEDER	NULL
,	NULL
M.J.	NULL
,	NULL
KRAUSE	NULL
,	NULL
R.	NULL
,	NULL
BIRD	NULL
,	NULL
LA	NULL
.	NULL

&	NULL
DEKABAN	NULL
,	NULL
G.A	NULL
.	NULL

(	NULL
1995b	NULL
)	NULL
.	NULL

Toxicity	NULL
of	NULL
sulphonamide-reactive	NULL
metabolites	NULL
in	NULL
HIV-infected	NULL
,	NULL
HTLV-infected	NULL
and	NULL
non-infected	NULL
cells	NULL
.	NULL

J.	NULL
Acg	NULL
.	NULL

Imm	NULL
.	NULL

Defic	NULL
.	NULL

Synd	NULL
.	NULL

Hum	NULL
.	NULL

Retrovirol	NULL
.	NULL

,	NULL
8	NULL
,	NULL
134-140	NULL
.	NULL

RIEDER	NULL
,	NULL
M.J.	NULL
,	NULL
UETRECHT	NULL
,	NULL
J.P.	NULL
,	NULL
SHEAR	NULL
,	NULL
N.H.	NULL
,	NULL
CANNON	NULL
,	NULL
M.	NULL
,	NULL
MILLER	NULL
,	NULL
M.	NULL
&	NULL
SPIELBERG	NULL
,	NULL
S.P	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

Diagnosis	NULL
of	NULL
sulphonamide	NULL
hypersensitivity	NULL
reactions	NULL
by	NULL
in	NULL
vitro	NULL
rechallenge	NULL
with	NULL
hydroxylamine	NULL
metabolites	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
110	NULL
,	NULL
286-289	NULL
.	NULL

RIEDER	NULL
,	NULL
M.J.	NULL
,	NULL
UETRECHT	NULL
,	NULL
J.P.	NULL
,	NULL
SHEAR	NULL
,	NULL
N.H.	NULL
&	NULL
SPIELBERG	NULL
,	NULL
S.P	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Synthesis	NULL
and	NULL
in	NULL
vitro	NULL
toxicity	NULL
of	NULL
hydroxylamine	NULL
metabolites	NULL
of	NULL
sulphonamides	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

,	NULL
244	NULL
,	NULL
724-728	NULL
.	NULL

SAIAG	NULL
,	NULL
P.	NULL
,	NULL
CAUMES	NULL
,	NULL
E.	NULL
,	NULL
CHOSIDOW	NULL
,	NULL
O.	NULL
,	NULL
REVUZ	NULL
,	NULL
J	NULL
.	NULL

&	NULL
ROUJEAU	NULL
,	NULL
J.C.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Drug-induced	NULL
toxic	NULL
epidermal	NULL
necrolysis	NULL
(	NULL
Lyell	NULL
syn-drome	NULL
)	NULL
in	NULL
patients	NULL
infected	NULL
with	NULL
the	NULL
human-immunodeficiency-virus	NULL
.	NULL

J	NULL
.	NULL

4m	NULL
.	NULL

Acad	NULL
.	NULL

Dermatol	NULL
.	NULL

,	NULL
26	NULL
,	NULL
567-574	NULL
.	NULL

SCHNYDER	NULL
,	NULL
D.	NULL
,	NULL
MAURI-HELLWEG	NULL
,	NULL
D.	NULL
,	NULL
ZANNI	NULL
,	NULL
M.P	NULL
.	NULL

,	NULL
BETTENS	NULL
,	NULL
F.	NULL
&	NULL
PICHLER	NULL
,	NULL
W.J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Direct	NULL
MHC-dependent	NULL
presentation	NULL
of	NULL
the	NULL
drug	NULL
sulphamethoxazole	NULL
to	NULL
human	NULL
«	NULL
f	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

J.	NULL
C/in	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
100	NULL
,	NULL
136-141	NULL
.	NULL

D.J	NULL
.	NULL

Naisbitt	NULL
et	NULL
al	NULL
SEARLE	NULL
,	NULL
J.	NULL
,	NULL
KERR	NULL
,	NULL
J.F.R	NULL
.	NULL

&	NULL
BISHIP	NULL
,	NULL
CJ	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
.	NULL

Necrosis	NULL
and	NULL
apoptosis	NULL
:	NULL
Distinct	NULL
modes	NULL
of	NULL
cell	NULL
death	NULL
with	NULL
fundamentally	NULL
different	NULL
significance	NULL
.	NULL

Pathol	NULL
.	NULL

Annu	NULL
.	NULL

,	NULL
17	NULL
,	NULL
229-259	NULL
.	NULL

SHEAR	NULL
,	NULL
NH	NULL
.	NULL

,	NULL
SPIELBERG	NULL
,	NULL
S.P	NULL
.	NULL

,	NULL
GRANT	NULL
,	NULL
D.M	NULL
.	NULL

,	NULL
TANG	NULL
,	NULL
BK	NULL
.	NULL

&	NULL
WILLOW	NULL
,	NULL
w.	NULL
(	NULL
1986	NULL
)	NULL
.	NULL

Differences	NULL
in	NULL
the	NULL
metabolism	NULL
of	NULL
sulphonamides	NULL
predisposing	NULL
to	NULL
idiosyncratic	NULL
toxicity	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
105	NULL
,	NULL
179-184	NULL
.	NULL

§SJOEBERG	NULL
,	NULL
B.	NULL
,	NULL
SUMERSKA	NULL
,	NULL
T.	NULL
,	NULL
BINNS	NULL
,	NULL
R.M	NULL
.	NULL

&	NULL
BALFOUR	NULL
,	NULL
B.M	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
.	NULL

Contact	NULL
sensitivity	NULL
in	NULL
the	NULL
pig	NULL
.	NULL

II	NULL
.	NULL

Induction	NULL
by	NULL
intralymphatic	NULL
infusion	NULL
of	NULL
DNP-conjugated	NULL
cells	NULL
.	NULL

Int	NULL
.	NULL

Arch	NULL
.	NULL

Allergy	NULL
Appl	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
57	NULL
,	NULL
114-125	NULL
.	NULL

SMITH	NULL
,	NULL
G.H	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
infections	NULL
in	NULL
the	NULL
patient	NULL
with	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
.	NULL

Arch	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
154	NULL
,	NULL
949-973	NULL
.	NULL

SOMERVILLE	NULL
,	NULL
C.C	NULL
.	NULL

,	NULL
NISHINO	NULL
,	NULL
S.F	NULL
.	NULL

&	NULL
SPAIN	NULL
,	NULL
J.C.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Purification	NULL
and	NULL
characterisation	NULL
of	NULL
nitrobenzene	NULL
nitroreductase	NULL
from	NULL
Pseu-domonas	NULL
pseudoalcaligenes	NULL
J	NULL
$	NULL
45	NULL
.	NULL

J	NULL
.	NULL

Bacteriol	NULL
.	NULL

,	NULL
177	NULL
,	NULL
3837-3842	NULL
.	NULL

STAAL	NULL
,	NULL
FJ.T	NULL
.	NULL

,	NULL
ELA	NULL
,	NULL
S.W	NULL
.	NULL

,	NULL
ROEDERER	NULL
,	NULL
M.	NULL
,	NULL
ANDERSON	NULL
,	NULL
MT	NULL
.	NULL

,	NULL
HERZENBERG	NULL
,	NULL
LA	NULL
.	NULL

&	NULL
HERZENBERG	NULL
,	NULL
L.A.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Glutathione	NULL
deficiency	NULL
and	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Lancet	NULL
,	NULL
339	NULL
,	NULL
909-912	NULL
.	NULL

THOMPSON	NULL
,	NULL
D.	NULL
,	NULL
CONSTANTIN-TEODOSIU	NULL
,	NULL
D.	NULL
,	NULL
NORBECK	NULL
,	NULL
K.	NULL
,	NULL
SVENSSON	NULL
,	NULL
B	NULL
.	NULL

&	NULL
MOLDEUS	NULL
,	NULL
P.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Metabolic	NULL
activation	NULL
of	NULL
eugenol	NULL
by	NULL
myeloperoxidase	NULL
and	NULL
polymorphonuclear	NULL
leukocytes	NULL
.	NULL

Chem	NULL
.	NULL

Res	NULL
.	NULL

Toxicol	NULL
.	NULL

,	NULL
2	NULL
,	NULL
186-192	NULL
.	NULL

Sulphamethoxazole	NULL
binding	NULL
to	NULL
cells	NULL
1407	NULL
TINGLE	NULL
,	NULL
M.D	NULL
.	NULL

&	NULL
PARK	NULL
,	NULL
B.K	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
use	NULL
of	NULL
a	NULL
three	NULL
compartment	NULL
in	NULL
vitro	NULL
model	NULL
to	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
hepatic	NULL
drug	NULL
metabolism	NULL
in	NULL
drug-induced	NULL
blood	NULL
dyscrasias	NULL
.	NULL

Br	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
36	NULL
,	NULL
31	NULL
39	NULL
.	NULL

TSCHACHLER	NULL
,	NULL
E.	NULL
,	NULL
BERGSTRESSER	NULL
,	NULL
P.R	NULL
.	NULL

&	NULL
STINGL	NULL
,	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

HIV	NULL
related	NULL
skin	NULL
diseases	NULL
.	NULL

Lancet	NULL
,	NULL
348	NULL
,	NULL
659-663	NULL
.	NULL

UETRECHT	NULL
,	NULL
J.P.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
leukocyte	NULL
generated	NULL
reactive	NULL
metabolites	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
idiosyncratic	NULL
drug	NULL
reactions	NULL
.	NULL

Drug	NULL
Metab	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
24	NULL
,	NULL
299-366	NULL
.	NULL

WALMSLEY	NULL
,	NULL
S.L	NULL
.	NULL

,	NULL
WINN	NULL
,	NULL
LM	NULL
.	NULL

,	NULL
HATTISON	NULL
,	NULL
ML	NULL
.	NULL

,	NULL
UETRECHT	NULL
,	NULL
J.P.	NULL
&	NULL
WELLS	NULL
,	NULL
P.G	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Oxidative	NULL
stress	NULL
and	NULL
thiol	NULL
depletion	NULL
in	NULL
plasma	NULL
and	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
from	NULL
HIV-infected	NULL
patients	NULL
:	NULL
toxicological	NULL
and	NULL
pathological	NULL
implications	NULL
.	NULL

AIDS	NULL
,	NULL
11	NULL
,	NULL
1689-1697	NULL
.	NULL

WATSON	NULL
,	NULL
R.W.G	NULL
.	NULL

,	NULL
REDMOND	NULL
,	NULL
H.P	NULL
.	NULL

,	NULL
WANG	NULL
,	NULL
J.H	NULL
.	NULL

&	NULL
BOUCHIER-HAYES	NULL
,	NULL
D.	NULL
(	NULL
1996a	NULL
)	NULL
.	NULL

Mechanisms	NULL
involved	NULL
in	NULL
sodium	NULL
arsenite-induced	NULL
apoptosis	NULL
of	NULL
human	NULL
neutrophils	NULL
.	NULL

J.	NULL
Leukoc	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
60	NULL
,	NULL
625-632	NULL
.	NULL

WATSON	NULL
,	NULL
R.W.G	NULL
.	NULL

,	NULL
REDMOND	NULL
,	NULL
HP	NULL
.	NULL

,	NULL
WANG	NULL
,	NULL
J.H	NULL
.	NULL

,	NULL
CONDRON	NULL
,	NULL
C.	NULL
&	NULL
BOUCHIER-HAYES	NULL
,	NULL
D.	NULL
(	NULL
1996b	NULL
)	NULL
.	NULL

Neutrophils	NULL
undergo	NULL
apoptosis	NULL
following	NULL
ingestion	NULL
of	NULL
Escherichia	NULL
coli	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
156	NULL
,	NULL
3986-3992	NULL
.	NULL

(	NULL
Received	NULL
July	NULL
2	NULL
,	NULL
1998	NULL
Revised	NULL
October	NULL
9	NULL
,	NULL
1998	NULL
Accepted	NULL
January	NULL
7	NULL
,	NULL
1999	NULL
)	NULL

